

CURRICULUM VITAE

Name: Keith Alan Joiner

Citizenship: United States

Education:

May 1970 - B.A., Biology with Honors, University of Chicago

May 1974 - M.D., cum laude, University of Colorado

May 2003 - M.P.H., Masters in Health Policy and Administration, Yale
University School of Medicine

Masters Thesis: Research Funding by Newly Recruited Faculty at University
Medical Centers: Development of Models for Projecting and
Simulating Grant Revenues.

Board Certification:

American Board of Internal Medicine - October, 1977

American Board of Internal Medicine - Infectious Disease, October 1980

Brief Chronology of Employment:

- 1974 - 1975 Intern in Medicine, Royal Victoria Hospital, McGill University, Montreal, P.Q., Canada
- 1975 - 1976 Junior Assistant Resident in Medicine, Royal Victoria Hospital, McGill University, Montreal, P.Q., Canada
- 1976 - 1977 Senior Assistant Resident in Medicine, Mary Hitchcock Memorial Hospital, Dartmouth Medical School, Hanover, New Hampshire
- 1977 - 1980 Clinical and Research Fellow in Infectious Disease, Tufts-New England Medical Center, Boston, Massachusetts
- 1980 - 1980 Assistant Professor of Medicine, Tufts University School of Medicine on IPA as researcher, NIAID, NIH
- 1980 - 1987 Senior Investigator, Laboratory of Clinical Investigation, Public Health Service, NIAID, NIH
- 1989 - 1989 Sabbatical, Laboratory of Ira Mellman, Dept. of Cell Biology, Yale University School of Medicine
- 1987 - 1989 Senior Investigator, Head, Unit of Microbial Pathogenesis Laboratory of Parasitic Diseases, NIAID, NIH
- 1989 - 2004 Professor of Medicine and Chief, Section of Infectious Diseases, Yale University School of Medicine
- 1991 - 2004 Professor of Epidemiology and Public Health, Yale University School of Medicine
- 1994 - 1995 Sabbatical, Laboratory of Peter Novick, Dept. of Cell Biology, Yale University School of Medicine
- 1995 - 2004 Professor of Cell Biology, Yale University School of Medicine
- 1999 - 2004 Associate Chairman, Dept. of Medicine, Yale University School of Medicine

- 1999 – 2004 Founder and Director, Investigative Medicine Program, Yale University School of Medicine
- 2004 – 2008 Dean, College of Medicine, University of Arizona
- 2007 – 2008 Vice Provost for Medical Affairs, University of Arizona
- 2006 – 2009 Principal Investigator, Health Research Alliance Arizona (Arizona CTSA program)
- 2004 – Professor of Cellular and Molecular Medicine, College of Medicine, and Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona
- 2009 - 2010 Senior Scholar, Association of Academic Health Centers, Washington, DC
- 2010 - 2014 Co-Director, Center for Management Innovations in Health Care, Eller College of Management, University of Arizona
- 2012 - Professor of Economics, University of Arizona
- 2014-2016 Director, Center for Management Innovations in Health Care, Eller College of Management, University of Arizona

Societies/Associations:

National:

- American Association for Advancement of Science – fellow (AAAS)
- American Association of Medical Colleges (AAMC)
- American Society for Cell Biology (ASCB)
- American Society for Clinical Investigation (ASCI)
- American Society for Microbiology (ASM)
- Association of Academic Health Centers (AAHC)
- Association of American Physicians (AAP)
- Association of Governing Boards of Universities and Colleges (AGB)
- Association of Subspecialty Professors (ASP)
- Infectious Disease Society of America – fellow (IDSA)
- Interurban Clinical Club (ICC)
- Society of Medical Administrators (SOMA)
- American Economic Association (AEA)

Regional:

- Arizona Association of Arts and Sciences (AASTA)
- Arizona Medical Society (ARMA)
- Arizona Latin American Medical Society (ALMA)
- Pima County Medical Society (PCMS)

Professional Honors or Recognition:

- 1972 Stoiber Award - outstanding student in medical class in primary clinical year
- 1974 Alpha Omega Alpha
- 1974 Waring Society - honorary medical society, University of Colorado
- 1985 International Endotoxin Society, Charter Member

- 1986 Fellow, Infectious Disease Society of America (IDSA)
- 1987 American Society for Clinical Investigation (ASCI)
- 1988 Commendation Medal - United States Public Health Service
- 1994-96 Co-Director, Cell Biology Section, Biology of Parasitism, Woods Hole, MA
- 1995-00 Burroughs Wellcome Scholar Award in Molecular Parasitology
- 1996 Fellow, American Association for the Advancement of Science
- 1993-96 Training Program Directors Committee, Infectious Disease Society of America
- 1996-00 Chairman, Training Program Directors Committee, Infectious Disease Society of America
- 1997 Organizer, Second Louis Pasteur Conference, Paris, Oct. 1998
- 1999 Interurban Clinical Club
- 2000-04 Waldemar Von Zedtwitz Professor of Medicine
- 2000-03 New Haven Councilor, Interurban Clinical Club
- 2001 Association of American Physicians (AAP)
- 2001 – Faculty of 1000
- 2001-05 Burroughs Wellcome Fund New Initiatives in Malaria Research Award
- 2001-05 Ellison Foundation Senior Scholar in Global Infectious Diseases
- 2004 – Elected to Southern Arizona Leadership Council
- 2005 – Named to Valley Influentials – Phoenix Business Journal
- 2005 – “*Top NIH Grantee*”, above the 95th percentile in distribution of NIH grant funds over the last 25 years
- 2006 – Cure Awardee, American Diabetes Association
- 2007 – Society of Medical Administrators (SOMA)

Review Panels/Advisory Groups/Study Sections:

- 1984–91 Ad Hoc reviewer, National Science Foundation
- 1985 –, Ad Hoc reviewer, Veterans Affairs Merit Review and Research Career Development Award
- 1986 – Ad Hoc reviewer, National Institutes of Dental Research, National Cancer Institute, National Institute for Allergy and Infectious Diseases, National Heart, Lung and Blood Institute
- 1990 Advisory Panel for National Cooperative Drug Discovery Group for Opportunistic Infections Program, NIAID
- 1993 External Advisory Panel, Sexually Transmitted Diseases Program, NIAID, NIH
- 1995-96 External Advisory Panel for Harvard Medical School Department of Tropical Health
- 1995-96 External Advisory Panel for Office of AIDS Research.
1998, Special NIH Study Section, Microbial Genomics
- 1995-99 Scientific Advisor, Development of Therapies Against *Cryptosporidium parvum*, 5U01AI033384, Tufts University School of Medicine, S. Tzipori, PI.
- 1996-98 Scientific Review Panel, Deutsche Forschungsgemeinschaft, Berlin, Germany

- 1997-01 Member, NIH AIDS Related Research 4 - Opportunistic Infections Study Section, NIAID
- 1997 NIAID Sexually Transmitted Diseases Program External Evaluation Committee
- 1996-99 American Council for Graduate Medical Education (ACGME)/Residency Review Committee (RRC) Pre-Reviewer for Infectious Diseases Fellowship Programs
- 1999-03 Scientific Advisory Panel, Barrier Function of the GI Tract in Health and Disease, 5PO1DK033506, Harvard Medical School, Allan Walker, Principal Investigator
- 1999-03 Scientific Advisors Panel, Cryptosporidium parvum Genome Sequencing Project, UO1AI046418, Virginia Commonwealth University, G. Buck, P.I.
- 1999 Site Visit Panel– Laboratory of Cellular and Molecular Biophysics, NICHD, NIH
- 2002-03 Chairman, RRC Task Force, Infectious Diseases Society of America
- 2003-04 Steering Committee, New England Regional Center for Excellence
- 2003-04 Selection Committee, New England Regional Center for Excellence
- 2003-04 Advisory Board, Scholars in Clinical Science Program, Harvard Medical School

Editorial Boards:

Current:

2011- Academic Medicine

Past:

- 1989-92 Infection and Immunity.
- 1990-93 Journal of Immunology.
- 1992-97 Infectious Agents and Diseases, Senior Editor.
- 1995-04 Journal of Cell Biology, Monitoring Editor.
- 1999-04 Cellular Microbiology, Editorial Board
- 2000-04 Current Drug Targets – Infectious Disorders, Editorial Board
- 2002-04 Parasite Cell Biology, Editorial Board

Consultantships/Advisory Boards:

Current:

Association of Academic Health Centers, Washington, DC
LarsenAllen, Minneapolis, MN

Past:

Biowhittaker, Inc. Walkersville, MD
Genaissance Pharmaceuticals, New Haven, CT
Gerson Lehrman Group Council of Healthcare Advisors
Intrabiotics Pharmaceuticals, Menlo Park, CA

National Center for Genome Resources (NCGR), Sante Fe, NM
Tribeca, NY, NY
Ultrabiotics, New Haven, CT
Vion Pharmaceuticals, New Haven, CT

Committees (Since 1990):

National:

- 1990-95 Program Committee, Interscience Conference on Antimicrobial Agents and Chemotherapy
- 1995-96 Chairman, New England Infectious Disease Program Directors Regional Conference
- 1996-00 Chairman, Training Program Directors Committee, Infectious Disease Society of America
- 1996-97 Chairman, National Infectious Diseases Program Directors Conference
- 1996-00 Councilors Committee, Association of Subspecialty Professors (ASP)
- 1998 Infectious Diseases Society of America Fellowship and New Investigator Awards Committee
- 1998-00 American Society for Microbiology Fellowship Awards Committee
- 1999-00 Research Committee, Association of Professors of Medicine (APM)
- 2000-03 Interurban Clinical Club Councilor
- 2001-04 Steering Committee, NIH K30 (Clinical Research Curriculum Award) Principal Investigators
- 2006 – Strategic Planning Committee, Association of Academic Health Centers
- 2007– Policy Assembly, Association of Academic Health Centers
- 2007 – Annual Meeting Program Committee Chair, Association of Academic Health Centers

Arizona Statewide/Regional Boards/Advisory Committees:

American Diabetes Association, Executive Committee, Tucson Chapter
Arizona Medical Association Board
Arizona Biosciences Steering Committee
Coordinating Committee, Phoenix Biomedical Campus
Health Care Task Force, Southern Arizona Leadership Council
Phoenix Biomedical Campus Advisory Board
Pima County Medical Society Board
Piper Trust Steering Committee
Southern Arizona Biosciences Steering Committee
Southern Arizona Leadership Council

University of Arizona Boards/Committees/Working Groups

Advanced Research Institute for Biomedical Imaging, (Chair) Executive Committee
Arizona Clinical Research Training Program Steering Committee
BIO5 Advisory Board
Critical Path Institute Advisory Committee
Dean's Academic Council

Dean's Development Committee
Dean's Health Sciences Academic Council
Directors Board, University of Arizona Foundation
Investment Committee, University of Arizona Foundation
McKnight Brain Institute Advisory Board
President's Cabinet
University of Arizona Clinical and Translational Research and Educational
Consortium Executive Working Group
University of Arizona Clinical and Translational Research and Educational
Consortium Advisory Board (Chair)
College Advisory Committee, Eller College of Management
Chair, Online Undergraduate Task Force

University of Arizona Health Sciences Boards/Committees

Clinical Issues Committee
Faculty Practice Committee (Chair)
University Medical Center Medical Executive Committee
University Medical Center Board
University Physicians Healthcare Board
University Physicians Healthcare Compensation Committee
University Physicians Hospital, Kino campus, Advisory Board
University Physicians Hospital, Kino campus, Medical Executive Committee
Joint Strategic Planning Committee, University Medical Center, University
Physicians Healthcare, College of Medicine

University/Hospital – Yale University:

1989-96 Microbiology Task Force
1989-90 Chairman, Yale New Haven Hospital AIDS Program Formation
Committee
1990-93 Medical School Tenured Faculty Appointment and Promotions
Committee
1993-95 Chairman, Microbial Pathogenesis Task Force
1994-96 Yale University School of Medicine Fellowship Awards Committee
1995-96 Pharmacy and Therapeutics Subcommittee for evaluation of new
therapeutics for sepsis, YNHH
1995-96 Chairman, Microbial Pathogenesis Search Committee, YSM
1997-98 Steering Committee for Evaluation and Design of Imaging Facilities at
Yale Medical School
1998-99 Co-Chairman, Yale Medical School Congress Avenue Building Design
Committee
1998-99 Yale School of Medicine Virology Task Force
1999 Biological Sciences Advisory Committee, Yale University
1999-04 Advisory Board, Hartford/NIA Geriatric Fellowship Program, YSM
2000-01 Chairman, Yale New Haven Hospital Epidemiology Search
Committee, YSM
2001-04 Steering Committee for Masters Degree in Clinical Investigation,
YSM

- 2001 Committee for Review of Biosafety Level 3 Laboratory and Animal Facilities, YSM
- 2002-03 Dean's working group on Sponsored Research, YSM
- 2002-04 Curriculum Design Committee, School Wide-Objectives Working Group; Subgroup Chair for LCME Skills Working Group
- 2003-04 Operations Committee, Yale New Haven Hospital/Department of Internal Medicine
- 2003 Winston Churchill Foundation Scholarship Committee, Yale University
- 2003-04 Search Committee, Chair for Cardiology Program
- 2003-04 Step Down Unit Committee, Yale New Haven Hospital/Department of Internal Medicine

Departmental – Yale University:

- 1993-97 Department of Internal Medicine Appointment and Promotions Committee
- 1994-95 Chairman, Committee for Review of Structure and Scope of Subspecialty Fellowship Training
- 1997-01 Departmental Space Allotment Committee
- 1999 Oncology Section Review Committee
- 1999-02 Internship Selection Committee
- 2000-01 Congress Avenue Building Space Allotment and Program Development Committee
- 2003 Chair, Global Health Initiatives
- 2003-04 Clinical Oversight Committee

Thesis/Qualifying Committees – Yale University:

- Adrian Lunn*, Dept. of Cell Biology, Yale University, 1990-1994
- David Resnick*, Biology Department, MIT, 1994-1996
- Kathy Rogers*, Dept. of Epidemiology and Public Health, Yale University, 1993-1996
- Jennifer Moorehead*, Dept. of Epidemiology and Public Health, Yale University, 1996-2002
- Charlotte Ariyan*, Investigative Medicine Program, Yale University, 2000-2003
- Varman Samuel*, Investigative Medicine Program, Yale University, 2000-2004
- Erica Herzog*, Investigative Medicine Program, Yale University 2001-2004
- Warren Lee*, Investigative Medicine Program, Yale University, 2001-2004
- Charlotte Frank*, Microbial Pathogenesis, Yale University, 2001-2004
- Hatim Hassan*, Investigative Medicine Program, Yale University 2002-2004
- Scott Lichtenberger*, Investigative Medicine Program, Yale University 2002-2004
- Scott Skibo*, Investigative Medicine Program, Yale University 2002-2004
- Anita Huttner*, Investigative Medicine Program, Yale University 2003-2004
- Edward Miller*, Investigative Medicine Program, Yale University 2003-2004
- Justin Paglino*, Investigative Medicine Program, Yale University 2003-2004
- Karin Schwartz*, Investigative Medicine Program, Yale University 2003-2004

Ph.D. Thesis Advisor – Yale University:

Chris Cohen, Dept. of Cell Biology, Yale University, 1991-1995 (Co-advisor with
Ira Mellman)

Samuel Lee, Investigative Medicine Program, Yale University, 2000-2004

Kristen Massimine, Dept. of Pharmacology, Yale University, 2002-2006

Thesis Committees - University of Arizona

Alex Hollingsworth, Economics

Jinling Lin, Economics

Teaching/Lectures – Yale University:

Investigative Medicine:

Course Director:

Seminars in Molecular Medicine (IMED 640a,b)

Translational Tools I (IMED 620a)

Infectious Diseases/Microbiology:

Roles of Microorganisms in the Living World (MBIO 642a)

Medical Microbiology (Medical Student Course)

Infectious Diseases Pathophysiology (Medical Student Course)

Cell Biology:

Cellular Basis of Human Biology (CBIO 502)

Molecular and Cellular Basis of Human Disease (CBIO 601)

Coursework Taken for Masters in Health Policy and Management , Yale University
(2002-2003):

Yale School of Management:

MGT 515b: Decision Analysis and Game Theory
MGT 525a: Competitive and Cooperative Strategies
MGT 527b: Strategic Management of Non Profit Organizations*
MGT 550a,b: Marketing Management
MGT 571b: Operations Management
MGT 611a: Policy Modeling*
MGT 661a: Health Law and Policy
MGT 803b: Leadership
MGT 808a: Making Decisions with Spreadsheets*
MGT 814a: Financial Statements for Non-Profit Organizations*
MGT 815a: Managerial Controls
MGT 816b: Strategic Considerations in Managerial Accounting
MGT 870a: Financial Accounting
MGT 886b: Designing and Managing Organizations
MGT 890a: Valuation, Investment, Corporate Finance and Options
* auditor

Yale School of Epidemiology and Public Health

BIS 505b: Introduction to Statistical Thinking II

HPA 510a: Health Care Policy and Health Systems

HPA 560b: Health Care Finance and Delivery
HPA 561b: Integrative Seminar in Health Services Management
HPA 570a: Cost-Effectiveness Analysis and Decision Making
HPA 586b: Microeconomics for Health Care Professionals

Teaching/Lectures - University of Arizona

MGMT 438/538: Health Care Management and Organization

ECON 427/527: Current Topics in Health Economics and Policy

Econ 599. Independent Study

Econ 566. Health Care Financing. Online MBA course

BNAD 597. Business Consulting Project

Faculty Advisory Role - University of Arizona

Faculty Advisor, MBA Advanced Field Project, Tucson Medical Center -
Accountable Care Organization. 5 Projects

Faculty Advisor, MBA Advanced Field Project, Scriptsave - Specialty Drugs

Faculty Advisor, MBA Advanced Field Project, Sunquest – Radiology
information systems

Faculty Advisor, Business in Medicine Club, University of Arizona College of
Medicine

Faculty Advisor, Health Care Management Club, Eller College of Management,
University of Arizona

Patents:

#04722890 Quantitative Assay for Human Terminal Complement Cascade

Date Issued: 02/02/88 Inventors: Sanders, Joiner, Frank and Hammer

#05624904 Method for Treating Gram Positive Septicemia

Date Issued: 04/29/97 Inventors: Krieger and Joiner

Past Funding:

Arizona Biomedical Scientist Development Program
Principal Investigator: Keith A. Joiner, M.D., M.P.H.
Agency: U. S. Department of Health and Human Services Office of National
Center on Minority and Health Disparities
Type: 1S22MD002231-01
Period: 7/1/06-6/30/09
Total Direct Costs: \$312,500

NIH RO1 AI30060-1: Cell Attachment and Invasion by *T. gondii*
P.I.: Keith Joiner
Project Period: 8/1/90-7/31/93
Total Direct Costs: \$617,241

NIH R01 AI30060-4: Structure and Function of the *T. gondii* Vacuole Membrane
PI: Keith Joiner
Project Period: 8/1/93-7/31/97
Total Direct Costs: \$835,514

NIH RO1 AI30060-8: Secretion, Organelle Association and the *T. gondii* Vacuole
P.I.: Keith Joiner
Project Period: 8/1/97-6/30/02
Total Direct Costs: \$1,488,324

NIH 1 RO1 AI46416-02: Mechanism-Based Drug Selection and Design:
Nucleotide Salvage in *T. gondii*
P.I. Buddy Ullman
Project Period: 10/1/99 – 9/30/04
Subcontract to Joiner (10% effort)
Total Costs: \$3,464,575
Total Subcontract Costs: \$565,992

NIH 1 RO1 AI-48443-01: Uptake of host cell cholesterol by *T. gondii*
P.I. Keith Joiner (20% effort)
Project Period: 7/1/00 – 6/30/05
Direct Costs: \$225,000/year
Total Direct Costs: \$1,025,000

NIH U01 AI31808-01: Mechanism-Based Drug Selection and Design for *T. gondii*
P.I.: Keith Joiner
Project Period: 9/1/91-8/31/95
Total Direct Costs: \$2,325,190

NIH U01 AI318080-05: Mechanism-Based Drug Selection and Design for *T. gondii*

P.I.: Keith Joiner

Project Period: 9/1/95-9/30/99

Total Direct Costs: \$2, 980,732

NIH R03 TW01000-01: Protein Targeting to and Through the *T. gondii* PVM

P.I.: Keith Joiner

Project Period: 7/1/98–6/30/01

Total Direct Costs: \$60,000

NIH RO3 TW01594-01: Rhoptry biogenesis in *Toxoplasma gondii*

P.I. Keith Joiner (35% effort – concurrent with AI30060)

Project Period: 4/1/01 – 3/31/04

Direct Costs: \$32,000/year

Total Direct Costs: \$94,700

NIH 1 K30 HL04145-02: Training in Clinical Investigation for Physician Scientists

P.I. Keith Joiner (25% effort)

Project Period: 6/01/99 – 5/31/2004

Direct Costs: \$200,000/year

Total Direct Costs: \$925,925

Burroughs Wellcome Fund Scholar Award in Molecular Parasitology

P.I.: Keith Joiner

Project Period: 7/1/95-6/30/00

Total Direct Costs: \$400,000

NIH T32 AI07517: Training in the Pathogenesis of Infectious Diseases

P.I.: Keith Joiner

Project Period: 7/1/07-6/30/02

Total Direct Costs: \$740,065

Burroughs Wellcome Fund 1002774: New Initiatives in Malaria Research: Hemoglobin Uptake in *Plasmodium*

P.I. Keith Joiner (10% effort)

Project Period: 7/1/01-6/30/07 (2 year no cost extension)

Direct Costs: \$100,000/year

Total Direct Costs: \$400,000

1NIH P20RR023482-01, Arizona Clinical and Translational Science Award Planning Grant

Co-P.I., Keith Joiner and Jeffrey Trent (Translational Genomics Research Institute)

Project Period: 11/1/06 – 10/31/07

Direct Costs: \$150,000

Total Direct Costs: \$150,000

Translational Research on AB Metabolism

Principal Investigator: Joseph Rogers, Ph.D.

Consultant: Keith A. Joiner, M.D., M.P.H.

Agency: Sun Health Research Institute

Period: 7/1/05-6/30/08

Subcontractor: Arizona Biomedical Research Commission (ABRC)

Total Direct Costs: \$44,000

NIH 5 RO1 AI30060-12: Phospholipid metabolism and traffic in *T. gondii*

P.I.: Keith Joiner (20% effort)

Project Period: 8/1/02 - 7/31/08 (no cost extension)

Direct Costs: \$331,000/year

Total Direct Costs: \$1,448,324

Ellison Foundation Senior Scholar in Global Infectious Diseases: Development of new genetic tools to identify nutrient uptake pathways in malaria parasites

Co-P.I.: Keith Joiner and Elisabetta Ullu

Project Period: 10/1/01-9/30/08 (on three year no cost extension)

Direct Costs: \$150,000/year

Total Direct Costs: \$600,000

Current Research Interests:

Healthcare incentive system design and implementation

Evaluation of academic health center performance

Bibliography:

1. Atencio, A.C., Joiner, K. and Reeve, E.B.: Experimental and control system studies of plasma fibrinogen regulation in rabbits. *Am. J. Physiol.* 216: 764-772, 1969.
2. Joiner, K.A. and Reeve, E.B.: A quantitative model of calcium and phosphate metabolism in man. *J. of Dynamic Systems, Measurement and Control.* Sept. 1973.
3. Reeve, E.B. and Joiner, K.A.: A quantitative model of calcium and phosphate metabolism. In *Regulation and Control in Physiologic Systems.* A.S. Iberall and A.C. Guyton, Editors, pp. 39-43, 1973.
4. Joiner, K.A. and Gorbach, S.L.: Antimicrobial therapy of digestive diseases. *Clinics in Gastroenterol.* 1: 1, 1979.
5. Joiner, K.A., Shahon, R.A. and Gelfand, J.A.: A sensitive micro-assay for the murine alternative complement pathway. *J. Immunologic Methods.* 31: 283-290, 1979.
6. Gorbach, S.L. and Joiner, K.A.: Acute septic complications in gastrointestinal emergencies. *Advances in the Biosciences Vol. 27, Gastrointestinal Emergencies.* F.R. Barany et al ed. Pergamon Press. Oxford and New York, 1980.
7. Joiner, K.A. and Gorbach, S.L.: Infections of the gastrointestinal tract. In: *Antimicrobial Therapy.* B.M. Kagan, Editor, 3rd Edition, 1980.
8. Joiner, K.A., Onderdonk, A.B., Gelfand, J.A., Bartlett, J.G. and Gorbach, S.L.: A quantitative model for subcutaneous abscess formation in mice. *Br. J. Exp. Path.* 61: 97-107, 1980.
9. Joiner, K.A. and Gorbach, S.L.: Indications for antimicrobial therapy of gastrointestinal diseases. *Seminars in Infectious Disease.* L. Weinstein, Editor, Vol. 3, Chapter 5, 1980.
10. Joiner, K.A., Gelfand, J.A., Onderdonk, A.B., Bartlett, J.G. and Gorbach, S.L.: Host factors in the formation of abscesses. *J. Infect. Dis.* 142: 40-49, 1980.
11. Joiner, K.A. and Gelfand, J.A.: Effect of cobra venom factor administration on alternative complement pathway function in mice. *Immunological Communications.* 9: 277-281, 1980.
12. Joiner, K.S. and Wolff, S.M.: Role of endotoxin in human disease and its therapy. *Augmenting Agents in Cancer Therapy: Current Status and Future Prospects,* Bethesda, MD. March 11-14, 1980.
13. Joiner, K.A. and Gorbach, S.L.: Acute septic complications of gastrointestinal emergencies: *Clinics in Gastroenterology.* 10: 93, 1981.

14. Joiner, K.A., Lowe, B., Dzink, J. and Bartlett, J.G.: Antibiotic levels in infected and sterile subcutaneous abscesses in mice. *J. Infect. Dis.* 143: 487, 1981.
15. Joiner, K.A., Gelfand, J.A., Bartlett, J.G. and Gorbach, S.L.: The effect of corticosteroids on subcutaneous abscess formation in the mouse. *Br. J. Exp. Path.* 62: 222, 1981.
16. Joiner, K.A., Hawiger, A. and Gelfand, J.A.: Activation of the alternative complement pathway by blood culture isolates of *Bacteroides fragilis*. *Infection and Immunity.* 34: 303-305, 1981.
17. Joiner, K.A., Lowe, B., Dzink, J. and Bartlett, J.G.: Comparative efficacy of ten antimicrobial agents in experimental *Bacteroides fragilis* infections. *J. Infect. Dis.* 145: 561-568, 1982.
18. Joiner, K.A., Hammer, C.H., Brown, E.J., Cole, R.M. and Frank, M.M.: Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from *Salmonella minnesota* S218 without causing bacterial death. *J. Exp. Med.* 155: 797-808, 1982.
19. Joiner, K.A., Hammer, C.H., Brown, E.J., and Frank, M.M.: Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of *Salmonella minnesota* S218 because the terminal complex does not insert into the bacterial outer membrane. *J. Exp. Med.* 155: 809-819, 1982.
20. Joiner, K.A., McAdam, K.P.W.J. and Kasper, D.L.: Lipopolysaccharides from *Bacteroides fragilis* are mitogenic for spleen cells from endotoxin responder and nonresponder mice. *Infect. Immun.* 36: 1139-1145, 1982.
21. Bartlett, J.G., Joiner, K.A., Dezfulian, M. and Marien, G.J.R.: Efficacy of Moxalactam in an animal model of subcutaneous abscesses: penetration into infected sites and in vivo activity versus *Bacteroides fragilis*. *Rev. Infect. Dis.* 4: S664-S669, 1983.
22. Bartlett, J.G., Marien, G.J.R., Dezfulian, M. and Joiner, K.A.: Relative efficacy of beta-lactam antimicrobial agents in two animal models of infections involving *Bacteroides fragilis*. *Rev. Infect. Dis.* 5: S338-S344, 1983.
23. Bartlett, J.G., Dezfulian, M. and Joiner, K.A.: Relative efficacy and critical interval of antimicrobial agents in experimental infections involving *Bacteroides fragilis*. *Arch. Surg.* 118: 181-184, 1983.
24. Joiner, K.A., Hawiger, A. and Gelfand, J.A.: A study of optimal reaction conditions for an assay of the human alternative complement pathway. Comparison with conventional complement determinations in normal individuals and in vitro and in vivo alternative pathway activation. *Am. J. Clin. Path.* 79: 65-72, 1983.

25. Brown, E.J., Berger, M., Joiner, K.A. and Cole, R.: Localization of C3 on *Streptococcus pneumoniae*: anticapsular antibody causes C3 deposition on the pneumococcal capsule. *Infection and Immunity*. 39: 403-409, 1983.
26. Joiner, K.A., Brown, E.J., Hammer, C.H., Warren, K.A. and Frank, M.M.: Studies on the mechanism of bacterial resistance to complement-mediated killing. III. C5b-9 deposits stably on rough and type 7 *S. pneumoniae* without causing bacterial killing. *J. Immunol.* 130: 845-849, 1983.
27. Brown, E.J., Joiner, K.A. and Frank, M.M.: Interaction of desialated guinea pig erythrocytes with the classical and alternative pathways of guinea pig complement in vivo and in vitro. *J. Clin. Invest.* 71: 1710-1719, 1983.
28. Lemanske, R.J. Jr., Joiner, K.A. and Kaliner, J.: The biologic activity of mast cell granules. IV. The effect of complement depletion on rat late phase reactions. *J. Immunol.* 130: 1881-1884, 1983.
29. Brown, E.J., Joiner, K.A., Gaither, T.A., Hammer, C.H. and Frank, M.M.: The interaction of C3b bound to pneumococci with factor H (beta-1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system. *J. Immunol.* 131: 409-415, 1983.
30. Joiner, K.A., Warren, K.A., Brown, E.J., Swanson, J. and Frank, M.M.: Studies on the mechanism of bacterial resistance to complement-mediated killing. IV. C5b-9 forms high molecular weight aggregates on serum resistant *Neisseria gonorrhoeae*. *J. Immunol.* 131:1443-1451, 1983.
31. Brown, E.J., Berger, J., Joiner, K.A. and Frank, M.M.: Classical complement pathway activation by antipneumococcal antibodies leads to covalent binding of C3b by antibody molecules. *Infect. Immun.* 42:594-598, 1983.
32. Joiner, K.A., Goldman, R.C., Hammer, C.H., Leive, L. and Frank, M.M.: Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab)² mediate killing of *E. coli* 0111B4 by the alternative complement pathway without increasing C5b-9 deposition. *J. Immunol.* 131:2563-2569, 1983.
33. Joiner, K.A., Goldman, R.C., Hammer, C.H., Leive, L. and Frank, M.M.: Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for *E. coli* 0111B4 by acting at a step prior to C5 cleavage. *J. Immunol.* 131:2570-2575, 1983.
34. Brown, E.J., Joiner, K.A. and Frank, M.M.: The role of complement in host defense against bacteria. *Springer Seminars in Immunopathology*. 6:349-360, 1983.
35. Frank, M.M., Joiner, K.A., Brown, E.J.: Parry-thrust - host defense and bacterial resistance to complement action. *Progress in Immunology*. V. p.387-396, 1983.

36. Brown, E.J., Joiner, K.A. and Frank, M.M.: Complement. In Paul, W.E. (Ed.): Fundamental Immunology. New York, Raven Press, pp. 645-668, 1984.
37. Shafer, W.M., Joiner, K., Guymon, L.F., Cohen, M.S. and Sparling, P.F.: Serum sensitivity of *Neisseria gonorrhoeae*: role of lipopolysaccharide. J. Infect. Dis. 149:175-183, 1984.
38. Joiner, K.A., Goldman, R., Schmetz, M., Berger, M., Frank, M.M., and Leive, L.: A quantitative analysis of C3 binding to surface polysaccharide, lipopolysaccharide, and outer membrane protein of *E. coli* O111B4. J. Immunol. 132:369-375, 1984.
39. Joiner, K.A., Brown, E.B., Frank, M.M.: Complement and bacteria: Biology and chemistry of host defense. Ann. Rev. of Immunol. 2:461-491.
40. Goldman, R.C., Joiner, K., and Leive, L.: Serum-resistant variants of *Escherichia coli* O111 contain more lipid A-core and greater coverage of lipid A-core with O antigen. J. Bacteriol. 159:877-882, 1984.
41. Joiner, K.A., Schmetz, M.A., Goldman, R.C., Leive, L., and Frank, M.M.: Studies on the mechanism of bacterial resistance to complement mediated killing: Inserted C5b-9 correlates with killing for *E. coli* O111B4 varying in O antigen capsule and O polysaccharide coverage of lipid A core oligosaccharide. Infect. Immun. 45:113-117, 1984.
42. Butler, T., Joiner, K.A., Malany, M., Bartlett, J. and Tally, F.: Transfer of tetracycline or clindamycin resistance among *Bacteroides fragilis* in experimental abscesses. J. Infect. Dis. 150:20-24, 1984.
43. Joiner, KA and Frank, MM: Mechanisms of bacterial resistance to complement-mediated killing. The Pathogenesis of Bacterial Infections. Bayer-Symposium VIII., Jackson, GG, and Thomas, H., editors, pgs. 122-136, 1984
44. Joiner, K.A. and Bartlett, J.G.: Evaluation of antimicrobial agents in animal models involving *Bacteroides fragilis*. South East Asian Journal of Surgery. Supplement V.8, p.96-102, 1984.
45. Joiner, K.A., Warren, K.A., Frank, M.M. and Rice, P.: Blocking IgG enhances complement consumption and deposition on *Neisseria gonorrhoeae* (GC). The Pathogenic Neisseriae, Proceedings of the 4th International Symposium. Asilomar, CA, 21-25 Oct., 1984.
46. Joiner, K.A. and Frank, M.M.: Mechanisms of bactericidal resistance to complement-mediated killing. The Pathogenesis of Bacterial Infections. Ed. G.G. Jackson and H. Thomas, Bayer Symposium VIII, Springer, Verlag Berlin, pp.122-137, 1985.

47. Shult, P.A. Dick, E.C., Joiner, K.A. and Busse, W.W.: Role of serum in influenza A stimulation of polymorphonuclear leukocyte, luminol-dependent chemiluminescence. *Am. Rev. Resp. Dis.* 131:267-72, 1985.
48. Joiner, K.A., Warren, K.A., and Frank, M.M.: Bactericidal but not non-bactericidal C5b-9 is associated with distinctive outer membrane proteins in *Neisseria gonorrhoeae*. *J. Immunol.* 134:1920-1925, 1985.
49. Joiner, K.A., Warren, K.A. Tam, M. and Frank, M.M.: Monoclonal antibodies directed against gonococcal PI vary in bactericidal activity. *J. Immunol.* 134:3411-3419, 1985.
50. Joiner, K.A., Heiny, S., Kirchhoff, L. and Sher, A.: The 72Kd glycoprotein is the membrane acceptor site for C3 on *Trypanosoma cruzi* epimastigotes during alternative pathway activation in serum. *J. Exp. Med.* 161:1196-1212, 1985.
51. Joiner, K.A., Schmetz, M.A., Sanders, M.E., Murray, T., Hammer, C.H., Dourmashkin, R. and Frank, M.M.: Multimeric C9 is required for complement-mediated killing of a rough strain of *E. coli*. *Proc. Natl. Acad of Sci.* 82:4808-4812, 1985.
52. Joiner, K.A.: Studies on the mechanism of bacterial resistance to complement-mediated killing and on the mechanism of action of bactericidal antibody. *Current Topics in Microbiology and Immunology*, 121:100-133, 1985.
53. Joiner, K.A., Fries, L.F., Schmetz, M.A., and Frank, M.M.: IgG bearing covalently bound C3b has enhanced bactericidal activity for *Escherichia coli* 0111. *J. Exp. Med.* 162:877-889, 1985.
54. Joiner, K.A., Scales, R., Warren, K.A., Frank, M.M. and Rice, P.: Mechanism of action of blocking IgG for *Neisseria gonorrhoeae*. *J. Clin. Invest.* 76:1765-1772, 1985.
55. Joiner, K.A. and M.M. Frank. Mechanisms of bacterial resistance to complement-mediated killing. In *The Pathogenesis of Bacterial Infections*, 122-136 (1985), by Springer-Verlag Berlin Heidelberg, 1985.
56. Sanders, M.E., Schmetz, M.A., Hammer, C.H., Frank, M.M., and Joiner, K.A.: Quantitation of activation of the terminal complement pathway by ELISA, *J. Immun. Methods.* 85:245-256, 1985.
57. Joiner, K.A. and Frank, M.M.: 1986. Molecular mechanisms in the antibacterial action of complement. *Progress in Immunology VI. The 6th International Congress of Immunology, Toronto, July, 1986.* ed. B. Cinar and R.G. Miller, pp. 282-290.
58. Sanders, M.E., Koski, C.L., Robbins, D., Shin, M.L., Frank, M.M., and Joiner, K.A.: Activated terminal complement in cerebrospinal fluid in Guillain-Barre Syndrome and Multiple Sclerosis. *J. Immunol.* 136:4456-4459, 1986.

59. Joiner, K.A.: Role of complement in infectious diseases. In: Immunobiology of the Complement System. ed. G. Ross, Academic Press, Orlando, FL, 183-195, 1986.
60. Joiner, K.A., Grossman, N., Schmetz, M.A., and Leive, L.: C3 binds preferentially to long-chain lipopolysaccharide during alternative pathway activation by *Salmonella montevideo*. J. Immunol. 136:710-715, 1986.
61. Joiner, K.A., Sher, A., Gaither, T.G., and Hammer, C.H.: Evasion of alternative complement pathway by *Trypanosoma cruzi* results from inefficient binding of factor B. Proc. Natl. Acad. Sci. 83:6593-6597, 1986.
62. Sher, A., Hieny, S., Joiner, K.: Evasion of the alternative complement pathway by metacyclic trypomastigotes of *Trypanosoma cruzi*: Dependence on the developmentally regulated synthesis of surface protein and n-linked carbohydrate. J. Immunol. 137:2961-2967, 1986.
63. Schiller, N., and Joiner, K.A.: Interaction of serum sensitive and serum resistant *Pseudomonas aeruginosa* strains with complement. Infect. Immun. 54:689-694, 1986.
64. Sanders, M., Kopicky, J., Wigley, F., Shin, M., Frank, M., and Joiner, K.: Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy. J. Rheum. 13:1028-1034, 1986.
65. Joiner, K.A., Fries, L.F., and Frank, M.M.: Studies of antibody and complement function in host defense against bacterial infection. Immunology Letters 14:197-202, 1986.
66. Joiner, K.A., and Frank, M.M.: Serum resistance and the mechanism of action of bactericidal antibody. Bacterial Vaccines. J.B. Robbins, R. Schreerson, D. Klein, J. Sadoff and M.C. Hardegree, ed. 519-531, 1987. Praeger, New York.
67. Sher, A., Joiner, K., Kirchhoff, L.V., and Snary, D.: Immunobiologic properties of the 72k glycoprotein (GP-72) of *Trypanosoma cruzi*. Proceedings of UCLA Symposium on Molecular Strategies of Parasite Invasion, 169:311-321, 1987.
68. Grossman, N., Schmetz, M., Klima, E.N., Leive, L. and Joiner, K.A.: LPS size and distribution determines serum resistance in Salmonella. J. Bacteriol. 169:856-863, 1987.
69. Bloch, E.F., Schmetz, M., Foulds, J., Hammer, C.H., Frank, M.M., and Joiner, K.A.: Multimeric C9 within C5b-9 is required for inner membrane damage to *E. coli* J5 during complement killing. J. Immunol. 138:842-848, 1987.
70. Santi, P., Tosi, R., Hammer, C.H., Frank, M.M. and Joiner, K.A.: A complement-resistant Raji cell line is blocked at the step of C3 deposition. J. Immunol. 10:3385-3391, 1987.

71. Koski, C.L., Sanders, M.E., Swoveland, P.T., Shin, M.L., Frank, M.M. and Joiner, K.A.: Activation of membrane-attack complex of complement in patients with Guillain Barre Syndrome and other demyelinating neuropathies. *J. Clin. Invest.* 80: 1492-1497, 1987.
72. Frank, M.M., Joiner, K. and Hammer, C.: The function of antibody and complement in the lysis of bacteria. *Reviews of Infectious Diseases*, (Suppl.) suppl. 5; 9:S537-S545, 1987.
73. Judd, R.C., Tam, M. and Joiner, K.: Characterization of Protein I from serum sensitive and serum resistant transformants of *Neisseria gonorrhoeae*. *Infect. Immun.* 55:273-276, 1987.
74. Sanders, M.E., Alexander, E.L., Koski, C.L., Frank, M.M. and Joiner, K.A.: Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren's Syndrome or Systemic Lupus Erythematosus. *J. Immunol.* 138:2095-2099, 1987.
75. Danner, R.L., Joiner, K.A. and Parrillo, J.E.: The inhibition of endotoxin induced neutrophil priming by lipid X and 3-Aza-Lipid X. *J. Clin. Invest.* 80:605-612, 1987.
76. Rice, P.A., Blake, M.S., and Joiner, K.A. Mechanisms of stable serum resistance of *Neisseria gonorrhoeae*. *J. Microbiol.* 53:565-574, 1987.
77. Frank, M.M., and Joiner, K.A.: Role of complement in infectious diseases, *Rev. Infect. Dis.* 9:S537-S545, 1987.
78. Jimenez-Lucho, V.E., Joiner, K.A., Frank, M.M., and Leive, L.: C3b generation is affected by the structure of the O-antigen polysaccharide in lipopolysaccharide from salmonellae. *J. Immunol.* 139:1253-1259, 1987.
79. Brown, E.J. and Joiner, K.A.: Mechanisms of host resistance to bacterial infection, *Immunologic Diseases*, ed. M. Samter. Fourth Edition, Volume 1: 715-736, 1988.
80. Blaser, M.J., Smith, P.F., Repine, J.E. and Joiner, K.A.: Pathogenesis of *Campylobacter fetus* infections. II. Failure of encapsulated *Campylobacter fetus* to bind C3b explains serum and phagocytosis-resistance. *J. Clin. Invest.* 81:1434-1444, 1988.
81. Rice, P.A., Blake, M.S. and Joiner, K.A.: Mechanism of stable serum resistance of *Neisseria gonorrhoeae*. In *Proceedings of the 5th International Pathogenic Neisseria Conference*. J.T. Poolman et al, Eds., Kluwer Academic Publishers, Dordrecht, The Netherlands, 789-798, 1988.
82. Hitchcock, P.J., Boslego, J., Joiner, K.A., and Robinson, E.N.: Analyses of the immunoaccessibility of H8 antigen and of the functionality of H8 specific monoclonal antibody. In *Proceedings of the 5th International Pathogenic*

- Neisseria Conference. J.T. Poolman, et al,Eds., Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 513-552, 1988.
83. Rice, P.A., Blake, M.S. and Joiner, K.A.: Interactions of antibodies and complement on bacterial surfaces: Lessons from the gonococcus. In *Vaccines: New Concepts and Developments*. Proceedings of the 10th International Convocation of Immunology. H. Kohler and P. Loverdi, eds. Longman Scientific and Technical. Essex, England. 177-193, 1988.
 84. Joiner, K.: Mechanisms of bacterial resistance to complement-mediated killing. *UCLA Symposium on Bacterial Host Cell Interaction*, ed. M. Horwitz; Alan R. Liss, Inc. NY, 64:15-30, 1988.
 85. Alexander, E.L., Provost, T.T., Sanders, M.E., Frank, M.M., and Joiner, K.A.: Serum complement activation in central nervous system disease in Sjogren's Syndrome. *Am. J. Med.* 85:513-518, 1988.
 86. Rimoldi, M.T., Sher, A., Heiny, S., Hammer, C.H. and Joiner, K.: Developmentally regulated expression by *Trypanosoma cruzi* of molecules which accelerate the decay of complement C3 convertases. *Proc Natl. Acad Sci.* 85:193-197, 1988.
 87. Puentes, S., Sacks, D., daSilva, R. and Joiner, K.: Complement binding by two developmental stages of *Leishmania major* promastigotes varying in expression of a surface lipophosphoglycan. *J. Exp. Med.* 167:887-902, 1988.
 88. Joiner, K., Jimenez-Lucho, V., Grossman, N., Foulds, J., Frank, M., and Leive, L.: Salmonella and Complement: The critical influence of O-Polysaccharide within LPS. *Bacteria, Complement and the Phagocytic Cell*, ed. F. Cabello and C. Pruzzo. NATO ASI Series. Series H: Cell Biology, Vol. 24, 139-156, 1988.
 89. Joiner, K.A.: The molecular basis for interactions between parasites and the complement cascade, in *Biology of Parasitism*, ed. A. Sher and P. Englund. *MBO Lectures in Biology*, Alan R. Liss, Inc., N.Y., 9:309-320, 1988.
 90. Joiner, K.A., Dias da Silva, W., Rimoldi, M.T., Hammer, C.H., Sher, A. and Kipnis, T.L.: Biochemical characterization of a factor produced by trypomastigotes of *Trypanosoma cruzi* which accelerates the decay of complement C3 convertases. *J. Biol. Chem.* 263:11327-11335, 1988.
 91. Sanders, M.E., Alexander, E.L., Koski, L., Sano, Y. Shin, M. Frank, M. and Joiner, K.: Terminal complement complexes in cerebral spinal fluid in autoimmune nervous system diseases. *Annals NY Acad Sci.*, 540:387-388, 1988.
 92. Joiner, K.A.: Complement evasion by bacteria and parasites. *Ann. Rev. Microbiol.* 42:201-230, 1988.
 93. Schweinle, J.E. and Joiner, K.A.: Complement Bactericidal Activity and Bacterial Evasion of Complement. *ISI Atlas of Science (Immunology)* 1:106-110, 1988.

94. Puentes, S.M., Dwyer, D., Bates, P. and Joiner, K.: Binding and release of C3 from *Leishmania donovani* promastigotes during incubation in normal human serum. *J. Immunol.* 143:3743-3749, 1989.
95. Joiner, K.A., Puentes, S.M., Warren, K.A., Scales, R.A. and Judd, R.C.: Complement binding on serum sensitive and serum resistant transformants of *Neisseria gonorrhoeae*. *Microbial Pathogenesis.* 6:343-350, 1989.
96. Rimoldi, M.T., Tenner, A.T., Bobak, D. and Joiner, K.: Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by *Trypanosoma cruzi* trypomastigotes. *J. Clin. Invest.* 84:1982-1989, 1989.
97. Danner, R.L., Joiner, K.A., Rubin, M., Hathorn, J.W. and Parillo, J.E.: The purification, toxicity and anti-endotoxin activity of polymyxin B nonapeptide. *Antimicrob. Agents Chemo.* 33:1428-1434, 1989.
98. Schweinle, J.E., Hitchcock, P.J., Tenner, A.J., Hammer, C.H., Frank, M.M. and Joiner, K.A.: Interaction of *Neisseria gonorrhoeae* with classical complement components, C1 Inhibitor, and a monoclonal antibody directed against the Neisserial H.8. antigen. *J. Clin. Invest.* 83:397-403, 1989.
99. Alexander, E.L., Sanders, M.E., Joiner, K.A., Mayo, M.H., Hamilton, R.G., Provost, T.T.: Evidence for the activation of the complement pathway in inflammatory vascular disease in Sjogren's Syndrome. *J. Invest. Derm.* 1989.
100. Fuhrman, S.A., and Joiner, K.A.: *Toxoplasma gondii*: Mechanism of resistance to complement-mediated killing. *J. Immunol.* 142:940-947, 1989.
101. Joiner, K.A., Tartanian, A.B., Hammer, C.H., and Schweinle, J.E.: Multimeric C9 within C5b-9 deposits in unique locations within the cell wall of *Salmonella typhimurium*. *J. Immunol.* 142:4450-4457, 1989.
102. Joiner, K.A., Kipnis, T. L., Dias da Silva, W., Rimoldi, M.T., Hammer, C.H., and Sher, A.: Identification of membrane components of *Trypanosoma cruzi* which are modulators of the complement system. *Memorias do Instituto Oswaldo Cruz.* 1989.
103. Schiller, N.L., Hatch, R.A., and Joiner, K.A.: Complement activation and C3 binding by serum-sensitive and serum-resistant strains of *Pseudomonas aeruginosa*. *Infect. Immun.* 57:1707-1713, 1989.
104. Rimoldi, M.T., Tartanian, A.B., and Joiner, K.A.: Lytic IgG for trypomastigotes of *Trypanosoma cruzi* changes the form and extent of complement deposition. *Exp. Parasitol.* 68:160-167, 1989.
105. Joiner, K., Ganz, T., Albert, J. and Rotrosen, D.: The opsonizing ligand on *Salmonella typhimurium* influences incorporation of specific, but not azurophil, granule constituents into neutrophil phagosomes. *J. Cell Biol.* 109:2771-2782, 1989.

106. Joiner, K.A. and Schweinle, J.E.: Halogenation and proteolysis of complement component C3 on *Salmonella typhimurium* during phagocytosis by human neutrophils. *J. Immunol.* 142:3164-3170, 1989.
107. da Silva, R., Hall, B.F., Joiner, K.A., and Sacks, D.: CR1, the C3b receptor, mediates binding of infective *Leishmania major* metacyclic promastigotes to human macrophages. *J. Immunol.* 143:617-622, 1989.
108. Kuhlman, M. Joiner, K.A., and Ezekowitz, R.A.B.: The human mannose binding protein functions as an opsonin. *J. Exp. Med.* 169:1733-1745, 1989.
109. Schweinle, J.E., Ezekowitz, R.A.B., Tenner, A.J., Kuhlman, M. and Joiner, K.A.: Human mannose binding protein activates the alternative complement pathway on mannose rich isolates of Salmonellae. *J. Clin. Invest.* 84:1821-1829, 1989.
110. Fuhrman, S. and Joiner, K.: Complement Evasion by Protozoa. *Exp. Parasit.* 68:474-481, 1989.
111. Jiminez-Lucho, V. and Joiner, K.A.: LPS O-side chains and complement killing. in *The Bacteria, Vol. XI Molecular Basis of Bacterial Pathogenesis*. B. Iglewski and V. Clark, ed. Academic Press. pp 339-354, 1990.
112. Puentes, S.M., da Silva, R., Hammer, C.H., and Joiner, K.A.: Serum resistance of metacyclic stage *Leishmania major* promastigotes is due to release of C5b-9. *J. Immunol.* 145:4311-4316, 1990.
113. Joiner, K.A., S.A. Fuhrman, H. Mietinnen, L. L. Kasper, and I. Mellman.: *Toxoplasma gondii*: Fusion competence of vacuoles in Fc receptor transfected fibroblasts. *Science.* 249:641-646, 1990.
114. Joiner, K.A.: Cell Attachment and entry by *Toxoplasma gondii*. Molecular aspects of immunological host-parasite-interactions. In *Behring Institute Mitteilungen No. 88*, 20-26, 1991.
115. Joiner, K.A.: How do parasites enter cells? Microbial decision analysis at the molecular level. *Resident and Staff Physician.* 37: 23-29, 1991.
116. Hall, B.F. and Joiner, K.A.: Strategies of obligate intracellular parasites for evading host defenses. *Immunoparasitology Today ;Combined Issue of Immunology Today*, 12:, and *Parasitology Today*, 7, A22-A28, 1991.
117. Webster, P., Joiner, K. and Andrews, N.W.: Why do so many surface proteins of trypanosomids have GPI-Anchors? *Cell Biology International Reports* 15: 799-813, 1991.
118. Joiner, K.A.: Rhoptry lipids and parasitophorous vacuole formation: A Slippery Issue. *Parasitology Today.* 7:226-227, 1991.
119. Hall, B.F., Furtado, G.C., Joiner, K.J.: Characterization of host cell vacuolar membrane proteins surrounding different intracellular forms of *Trypanosoma*

- cruzi* in J774 Cells: Evidence for phagocytic receptor sorting during early stages of parasite entry. *J. Immunol.* 147: 4313-4321, 1991.
120. Joiner, K.A.: Other virulence factors. In *Infectious Diseases in Medicine and Surgery*. ed. Gorbach, Bartlett and Blacklow., W.B. Saunders, Co. Philadelphia, P.A. pp. 23-30, 1992.
 121. Furtado, G.C., Slowik, M., Kleinman, H.K. and Joiner, K.A.: Laminin enhances the binding of tachyzoites of *Toxoplasma gondii* to the murine macrophage cell line J774. *Infect. Immun.* 60:2337-2342, 1992.
 122. Hall, B.F., Webster, P., Ma, A.K., Joiner, K.A., and Andrews, N.W.: Desialylation of lysosomal membrane glycoproteins by *Trypanosoma cruzi*: A role for the surface neuraminidase in facilitating parasite entry into the cytoplasm. *J. Exp. Med.* 76:313-325, 1992.
 123. Furtado, G.C., Cao, Y. and Joiner, K.A.: Laminin on tachyzoites of *Toxoplasma gondii* mediates parasite binding to the $\beta 1$ integrin receptor $\alpha 6\beta 1$ on human foreskin fibroblasts and Chinese hamster ovary cells. *Infect. Immun.* 60:4925-4931, 1992.
 124. Joiner, K.A.: Cell entry by *Toxoplasma gondii*: All paths do not lead to success. *Immunobiology of Toxoplasma gondii Forum. Res. Immunol.* 144:34-38, 1993.
 125. Joiner, K.A.: The parasitophorous vacuole membrane surrounding *Toxoplasma gondii* - A specialized interface between parasite and cell. In *Toxoplasmosis*. ed. J.E. Smith, NATO ASI Series, vol. 78:73-82, 1993.
 126. Joiner, K.A. and Dubremetz, J.G.: *Toxoplasma gondii* - a parasite for the nineties. *Infect. Immun.* 61: 1169-1172, 1993.
 127. Tambourghi, D.V., Kipnis, T.L., Dias da Silva, W., Joiner, K.A., Sher, A., Heath, S., Hall, B.F., and Ogden, G.B. A partial cDNA clone of T-DAF, a developmentally regulated complement inhibitor of *Trypanosoma cruzi*, has genetic and functional similarities to the human complement inhibitor DAF. *Infect. Immun.* 61(9):3656-3663, 1993.
 128. Hall, B.F., Joiner, K.A., and Andrews, N.W. Developmentally regulated virulence factors of *Trypanosoma cruzi* and their relationship to evasion of host defenses. *J. Eukaryot. Microbiol.* 40:207-213, 1993.
 129. Dubremetz, J.F., Achbarou, A., Bermudes, D. and Joiner, K.A. Kinetics and pattern of organelle discharge during *Toxoplasma gondii*/host-cell interaction. *Parasitol. Res.* 79:402-408, 1993.
 130. Bermudes, D. and Joiner, K.A. The role of parasites in generating evolutionary novelty. *Parasitology Today.* 9:458-463, 1993.

131. Bloch, E.F., Rahbar, M., Wright, A.K., Patterson, A.M., Souza, R.F., Hammer, C.H., Gaither, T.A., and Joiner, K.A. Potassium cyanide protects *Escherichia coli* from complement killing by the inhibition of C3 convertase activity. *Immunol. Invest.* 22:127-149, 1993.
132. Schwab, J.C., Beckers, C.J.M. and Joiner, K.A.: The parasitophorous vacuole membrane surrounding intracellular *Toxoplasma gondii* functions as a molecular sieve. *Proc. Natl. Acad. Sci.* 91: 509-513,1994.
133. Joiner, K.A. Vacuolar membranes surrounding intracellular pathogens - Where do they come from and what do they do? *Infect. Agents Diseases*, 2:215-219, 1994.
134. Ossorio, P.N., Dubremetz, J.-F., and Joiner, K.A. A soluble secretory protein of the intracellular parasite *Toxoplasma gondii* associates with the parasitophorous vacuole membrane through hydrophobic interactions. *J. Biol. Chem.* 269:15350-15357, 1994.
135. Schwab, J. C., Cao, Y., Slowik, M. and Joiner, K.A. Localization of azithromycin in *Toxoplasma gondii* -infected cells. *Antimicrob. Agents Chemo.* 38 (7): 1620-1627, 1994.
136. High, K., Joiner, K.A., and Handschumacher, R.E., Joiner, K.A. Isolation, cDNA sequences, and biochemical characterization of the major cyclosporine binding proteins of *Toxoplasma gondii*. *J. Biol. Chem.* 269:9105-9112, 1994.
137. Beckers, C.J.M., Dubremetz, J.F., Mercereau-Puijalon, O., and Joiner, K.A. The *Toxoplasma gondii* protein ROP2 is associated with the parasitophorous vacuole membrane, surrounding intracellular stages, and is exposed to the host cell cytoplasm. *J. Cell Biol.* 127(4):947-961, 1994.
138. Dunne, D.W., Greenberg, J. , Resnick, D., Krieger, M. and Joiner, K.A. The type I macrophage scavenger binds to gram positive bacteria and recognizes cell surface lipoteichoic acid. *Proc. Natl. Acad. Sci.* 91: 1863-1867, 1994.
139. Joiner, K.A., Beckers, C.J.M., Bermudes, D., Ossorio, P.N., Schwab, J.C. and Dubremetz, J.F., Structure and function of the parasitophorous vacuole membrane (PVM) surrounding *Toxoplasma gondii*. *Annals NY Acad. Sci.* 730:1-6, 1994.
140. Joiner, K.A. Promoting laboratory research during infectious diseases fellowship training or Telling the truth about training in clinical research. *Infect. Agents Dis.*3(4): 163-167, 1994.
141. Bermudes, D., Dubremetz, J.F., Achbarou, A. and Joiner, K.A. Cloning of a cDNA encoding the dense granule protein GRA3 from *Toxoplasma gondii*. *Mol. Biochem. Parasitol.* 68(2):247-257,1994.
142. Cohen, C.J., Bacon, R., Clarke, M., Joiner, K. and Mellman, I. *Dictyostelium discoideum* mutants with conditional defects in phagocytosis. *J. Cell Biol.* 126(4):955-966, 1994.

143. Bermudes, D., Peck, K.R., Afifi-Afifi, M., Beckers, C.J.M., and Joiner, K.A. Tandemly repeated genes encode nucleoside triphosphate hydrolase isoforms secreted into the parasitophorous vacuole of *Toxoplasma gondii*. *J. Biol. Chem.* 269:29252-29260, 1994.
144. Beckers, C.J.M., Roos, D.S., Donald, R.G.K., Luft, B.J., Schwab, J.C., Cao, Y., and Joiner, K.A. Inhibition of cytoplasmic and organellar protein synthesis in *Toxoplasma gondii*: Implications for the target of macrolide antibiotics. *J. Clin. Invest.* 95:367-376, 1995.
145. Schwab, J.C., Afifi Afifi, M., Pizzorno, G., Handschumacher, R.E., and Joiner, K.A. Tachyzoites of the protozoan parasite *Toxoplasma gondii* possess a novel plasma membrane adenosine transporter. *Mol. Biochem. Parasitol.* 70:59-69, 1995.
146. Joiner, K.A.: Other virulence factors. In *Infectious Diseases in Medicine and Surgery*. ed. Gorbach, Bartlett and Blacklow. W.B. Saunders, Co. Philadelphia, PA., pp 18-28, 1995.
147. Polotsky, V.Y., Fischer, W., Ezekowitz, R.A.B., Joiner, K.A. Interactions of human mannose binding protein with lipoteichoic acids. *Infect. and Immun.* 64:380-383, 1996.
148. Samuel, B., Joiner, K.A: Toxoplasmosis. In *Conn's Current Therapy*. ed. Robert E. Rakel, M.D. Published by W. B. Saunders, Co. Philadelphia, PA, pp 160-66, 1997.
149. Joiner, KA., Bermudes, D., Sinai, A., Qi, H., Polotsky, V., and Beckers, CJM: Structure and function of the *T. gondii* vacuole. *Ann NY Acad Sci.* 797:1-7, 1996.
150. Greenberg, J., Fischer, W., Resnick, D., Krieger, M. and Joiner, KA.: Influence of lipoteichoic acid structure on recognition by the macrophage scavenger receptor. *Infect. Immun.* 64:3318-3325, 1996.
151. Silverman, J. and Joiner, K.A. *Toxoplasma/Host Cell Interaction*, In *Host Response to Intracellular Pathogens* ed. S.H.E. Kaufman, R.G. Landes, Austin, TX, p313-338, 1997.
152. Polotsky, V.Y., Belisle, J.T., Ezekowitz, R.A.B., and Joiner, K.A. Interaction of human mannose binding protein with *Mycobacterium avium*. *J. Infect. Dis.* 175:1159-68, 1997.
153. Sinai, A. and Joiner, K.A. Safe Haven: The cell biology of non-fusogenic pathogen vacuoles. *Annu. Rev. Microb.* 51: 415-62, 1997.
154. 154. Joiner, K.A. Membrane traffic in pathogen-infected cells. *J. Clin. Invest.* 99: 1814-1817, 1997.

155. Silverman, J., Hayes, M.L., Luft, B.J. and Joiner, KA. Characterization of the anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and PPIase-inhibiting activity: Possible role of a P-glycoprotein in Toxoplasma physiology. Antimicrob. Agents. Chemo. 41:1859-1866, 1997.
156. Beckers, CJM., Wakefield, T., Dubey, JP., and Joiner, KA. The expression of *Toxoplasma gondii* proteins in *Neospora caninum* and the identification of a gene encoding a novel rhoptry protein. Mol. Biochem. Parasitol. 89:209-223, 1997.
157. Sinai, A., Webster, P., and Joiner, KA. Association of host cell endoplasmic reticulum and mitochondria with the *Toxoplasma gondii* parasitophorous vacuole membrane - a high affinity interaction. J. Cell Sci. 110:2117-2128, 1997.
158. Karsten, V., Qi, H., Beckers, C.J.M. and Joiner, K.A. Targeting the secretory pathway of *Toxoplasma gondii*. Methods. 13:103-111, 1997.
159. Karsten, V. Qi, H., Beckers, CJM., Reddy, A., Dubremetz, JF., Webster, P. and Joiner, KA. The protozoan parasite *Toxoplasma gondii* targets proteins to dense granules and the vacuolar space using both conserved and unusual mechanisms. J. Cell Biol.141: 1323-1333, 1998.
160. Joiner, K.A., Powderly, W., Blaser, M., Klempner, M., Locksley, R., Mandell, G., Preheim, L., Remington, J., Slama, T., Steigbigel, N., and Bartlett, J.G. Fellowship training in Infectious Diseases: A report from the regional and national meetings of Infectious Disease division chiefs and program directors. Clin. Infect. Dis. 26:1060-1065, 1998.
161. Silverman, J.A., Qi, H., Riehl, A., Beckers, C.J.M., Nakaar, V. and Joiner, K.A. Induced activation of the *Toxoplasma gondii* nucleoside triphosphate hydrolase leads to depletion of host cell ATP levels and rapid exit of intracellular parasites from infected cells. J. Biol. Chem. 273: 12352-12359, 1998.
162. Nakaar, V., Bermudes, D., Peck, KR., and Joiner, K.A., Upstream elements required for expression of nucleoside triphosphate hydrolase genes of *Toxoplasma gondii*. Mol. Biochem. Parasitol. 92: 229-239, 1998.
163. Lingelbach, K. and Joiner, K.A. The parasitophorous vacuole membrane surrounding Plasmodium and Toxoplasma: An unusual compartment in infected cells. J. Cell Sci. 111: 1467-1475, 1998.
164. Naakar, V. Beckers, C.J.M., Polotsky, V., and Joiner, K.A. Basis for substrate specificity of the *Toxoplasma gondii* nucleoside triphosphate hydrolase. Mol Biochem. Parasitol. 97:209-220, 1998.
165. Chaturvedi, S., Qi, H., Hanson, P., Rodriguez, A., and Joiner, K.A. *Toxoplasma gondii* dense granules are secreted in a calcium independent fashion using the NSF/SNAP/SNARE/Rab machinery. J. Biol. Chem. 274: 2424-2431, 1999.

166. Nakaar, V., Samuel, B.U., Ngo, E.O., and Joiner, K.A. Targeted reduction of nucleoside triphosphate hydrolase by antisense RNA inhibits *Toxoplasma gondii* proliferation. *J. Biol. Chem.* 274: 5083-5087, 1999.
167. Joiner, K.A. Introduction to protozoan and helminthic diseases. Cecil Textbook of Medicine. Goldman, L, and Bennett, J.C., ed. W.B. Saunders, Philadelphia, 1999.
168. High, K.P. and Joiner, K.A. Meeting review: Integrating geriatrics into infectious diseases clinical training, research training, board certification and continuing education. *Clin. Infect. Dis.* 28:753-6, 1999.
169. Stedman, T. and Joiner, K.A. En route to the vacuole: Tracing the secretory pathway of *Toxoplasma gondii*. *Advances in Cell and Molecular Biology of Membranes and Organelles*. Ed. S. Gordon. JAI Press, Greenwich, CT. 6:233-261, 1999.
170. Ferguson, D.J.P., Cesbron, M-F., Dubremetz, J-F, Sibley, L.D., Joiner, K.A., and Wright, S. The expression and distribution of dense granule proteins in the enteric (coccidian) forms of *Toxoplasma gondii* in the small intestine of the cat. *Exp. Parasitol.* 91: 203-211, 1999.
171. Nee, P. and Joiner, K.A. Treatment of Toxoplasmosis. Current treatment options in infectious diseases. A. Tice and J. Griffiths, eds. Current Science, Inc. 1999.
172. Kaasch, A.J. and Joiner, K.A. Peroxisomes – a new organelle in the apicomplexan parasite *Toxoplasma gondii*. Targeting and subcellular localization of catalase. *J. Biol. Chem.* 275:1112-1118, 2000.
173. Ngo, H., Hoppe, H.C., and Joiner, K.A. Differential sorting and post-secretory targeting of proteins in parasitic invasion. *Trends Cell Biol.* 10: 67-72, 2000.
174. Ngo, H.M., Ngo, E.O., Bzik, D.J. and Joiner, K.A. *Toxoplasma gondii*: Are host cell adenosine nucleotides a source for purine salvage ? *Exp. Parasitol.* 95: 148-153, 2000.
175. Sinai, A.P., Paul, S., Rabinovitch, M., Kaplan, G., and Joiner, K.A. Co-infection of fibroblasts with *Coxiella burnetti* and *Toxoplasma gondii*: to each their own. *Microbes and Infection*, 2: 727-736, 2000.
176. Hoppe, H.C., Yang, M., Ngo, H.M., and Joiner, K.A. Targeting to rhoptry organelles of *Toxoplasma gondii* involves evolutionarily conserved mechanisms. *Nature Cell Biol.* 2: 449-456, 2000.
177. Montgomery, R.R., Palmarozza, R.E., Beck, D.S., Ngo, E.O., Joiner, K.A. and Malawista, S.E. Functional competence of peritoneal macrophages in murine Lyme borreliosis. *Inflammation.* 24:277-288, 2000.
178. Liendo, A. and Joiner, K.A. *Toxoplasma gondii*: conserved protein machinery in an unusual secretory pathway? *Microbes and Infection.* 2: 137-44, 2000.

179. Robibaro, B., Hoppe, H.C., Yang, M., Coppens, I., Ngô, H.M., Stedman, T.T. and Joiner, K.A. Endocytosis in different lifestyles of protozoan parasitism: role in nutrient uptake with special reference to *Toxoplasma gondii*. *Int. J. Parasitol.* 31:1343-1353, 2001
180. Kaasch, A.J. and Joiner, K.A. Protein targeting determinants in the secretory pathway of Apicomplexan parasites. *Curr. Opin. Microbiol.* 3:422-428, 2000
181. Coppens, I., Sinai, A.P. and Joiner, K.A. *Toxoplasma gondii* exploits host LDL-receptor-mediated endocytosis for cholesterol acquisition. *J. Cell Biol.* 149: 167-180, 2000.
182. Costa, S.T., Ausiello, D., Joiner, K., Neilson, E.G., Taylor, I., and Wenzel, R. Supporting research in departments of internal medicine: recommendations for NIH. *Am. J. Med.* 109: 178-180, 2000.
183. Hoppe, H.C. and Joiner, K.A. Cytoplasmic tail motifs mediate ER localization and export of transmembrane protein reporters in the protozoan parasite *Toxoplasma gondii*. *Cell. Microbiol.* 2:569-578, 2000.
184. Nakaar, V. and Joiner, K.A. Selection based on the expression of antisense hypoxanthine-xanthine-guanine phosphoribosyltransferase RNA in *Toxoplasma gondii*. *Mol. Bioch. Parasitol.* 110: 43-51, 2000.
185. van Dorren, G.G., Waller, R.F., Joiner, K.A., Roos, D.S. and McFadden, G.I. Traffic jams: Protein transport in *Plasmodium falciparum*. *Parasitol. Today.* 16: 421-7, 2000.
186. Joiner, K.A., W.E. Dismukes, B.E. Britigan, M.S. Cohen, W.D. Johnson, A.W. Karchmer, G.L. Mandell, W.E. Stamm. Adequacy of fellowship training: Results of a survey of recently graduated fellows. *Clin. Infect. Dis.* 32: 255-62, 2001.
187. Coppens, I. and Joiner, K.A. Host cell interactions in toxoplasmosis: New avenues for intervention. *Expert Rev. Mol. Med.* <http://www-ermm.cbcu.cam.ac.uk/01002277h.htm>
188. Quagliariello, V. and Joiner, K.A. Counterpoint: UNAFs—perspective and prevention (solicited letter) *Clin. Infect. Dis.* 5:755-6, 2001.
189. Sinai, A.P. and Joiner, K.A. The *Toxoplasma gondii* protein ROP2 mediates host organelle association with the parasitophorous vacuole membrane. *J. Cell.Biol.* 154:95-108, 2001.
190. Liendo, A., Stedman, T., Ngô, H. M., Chaturvedi, S., Hoppe, H.C., and Joiner, K.A. *Toxoplasma gondii* ADP-ribosylation factor mediates enhanced release of constitutively secreted dense granule proteins. *J. Biol. Chem.* 276:18272-18281, 2001.

191. Stedman, T. and Joiner, K.A. *Toxoplasma gondii* rab6 mutants selectively block dense granule protein transport from the Golgi and alter parasite cytokinesis. *J. Biol. Chem.* 278:5433-43,2003.
192. Nakaar, V., Ngô, H.M., Aronson, E.P., Coppens, I., Stedman, T.T., and Joiner, K.A. Pleiotropic effect due to targeted depletion of secretory rhoptry protein ROP2 in *Toxoplasma gondii*. *J. Cell Sci.* 116: 2311-20, 2003.
193. Ngô, H.M., Yang, M., Pypaert, M., Hoppe, H.C., and Joiner, K.A. Biogenesis of secretory organelles in an apicomplexan parasite is dependent on the AP-1 adaptin. *J. Biol. Chem.* 278:5343-5352, 2003.
194. Robibaro, B., Stedman, T.T., Coppens, I., Ngô, H.M., Pypaert, M., Bivona, T., Nam, H.W., and Joiner, K.A. *Toxoplasma gondii* Rab5 enhances cholesterol acquisition from host cells. *Cell. Microbiol.* 4:139-52, 2002.
195. Joiner, K.A. and Roos, D.S. Secretory traffic in the eukaryotic parasite *Toxoplasma gondii*: Less is more. Invited mini-review. *J. Cell Biol.* 157:557-63, 2002.
196. Joiner, K.A. Introduction to protozoan and helminthic diseases. In press, Cecil Textbook of Medicine. Goldman, L, and Bennett, J.C., ed. W.B. Saunders, Philadelphia, 2003.
197. Joiner, K.A., Haponik, E. and High, K.P. Integrating geriatrics and subspecialty internal medicine: Results of a survey on patient care practices, training, attitudes and research. *Am. J. Med.* 112:249-54, 2002.
198. Que, X., Ngo, H., Liu, Q., Engel, J., Brinen, L. Herdman, S., Hirata, K., Joiner, K.A., and Reed, S.L. The cathepsin B of *Toxoplasma gondii*, toxopain-1, is critical for parasite invasion and rhoptry protein processing. *J. Biol. Chem.* 277: 25791-7, 2002.
199. Atreay, C., Johnson, E.F., Irwin, J.J., Dow, A., Massimine, K.M., Coppens, I., Stempliuk, V., Beverly, S., Joiner, K.A., Shoichet, B.K, and Anderson, K.S. A molecular docking strategy identifies Eosin B as a non-active site inhibitor of protozoal bifunctional thymidylate synthase-dihydrofolate reductase. *J. Biol. Chem.* 278:14092-100, 2003.
200. Pelletier, L., Stern, C.A., Pypaert, M., Sheff, D., Ngô,H.M., Roper, N., He, C.Y., Toomre, D., Coppens, I., Roos, D.S., Joiner, K.A., and Warren, G. Golgi biogenesis in *Toxoplasma gondii*. *Nature.* 418: 549-52, 2002.
201. Coppens, I. and Joiner, K.A. Host but not parasite cholesterol controls *Toxoplasma* entry by modulating organelle discharge. *Mol. Biol. Cell.* 14:3804-20, 2003.

202. Ngô, H.M., Yang, M., and Joiner, K.A. Are rhoptries in apicomplexan parasites secretory granules or secretory lysosomal granules? *Mol. Micro.* 52: 1531-1541, 2004.
203. Lee, S.A., Wormsley, S., Kamoun, S., Joiner, K. and Wong, B. An analysis of the *Candida albicans* genome database for soluble secreted proteins using computer-based prediction algorithms. *Yeast*, 20:595-610, 2003.
204. Yang, M., Coppens, I., Wormsley, S., Baevova, P., Hoppe, H.C., and Joiner, K.A. The *Plasmodium falciparum* Vps4 homologue mediates multivesicular body formation. *J. Cell Sci.* 117:3831-8,2004.
205. Que, X., Wunderlich, A., Joiner, K.A., and Reed, S.L. Toxopain-1 is critical for *Toxoplasma gondii* infection in a novel chick embryo model of congenital toxoplasmosis. *Infect. Immun.* 72: 2915-21, 2004.
206. Nishikawa, Y., Xuenan, X., Vielemeyer, O., Suzuki, H., Joiner, K.A., and Nagasawa, H. The role of gamma interferon in the induction of host cell apoptosis by a *Toxoplasma gondii*-derived factor. *Int. J. Parasitol.* 33:1525-35,2003.
207. Vielemeyer, O., McIntosh, M.T., Joiner, K.A. and Coppens, I. Neutral lipid synthesis and storage in the intraerythrocytic stages of *Plasmodium falciparum*. *Mol. Biochem. Parasitol.* 135: 195-207, 2004.
208. Hinshaw, J.C., Suh, D.Y., Garnier, P., Buckner, F.S., Eastman, R.T., Matsuda, S.P., Joubert, B.M., Coppens, I., Joiner, K.A., Merali, S., Nash, T.E., and Prestwich, G.D., Oxidosqualene cyclase inhibitors as antimicrobial agents. *J. Med. Chem.* 46: 4240-3, 2003.
209. Karsten, V., Hegde, R.S., Sinai, A.P., Yang, M. and Joiner, K.A. Transmembrane domain modulates sorting of membrane proteins in *Toxoplasma gondii*. *J. Biol. Chem.* 279: 26052-7, 2004.
210. Joiner, K.A. Using utility theory to optimize a salary incentive plan for grant-funded faculty. *Acad. Med.* 79:652-660, 2004.
211. Joiner, K.A. Sponsored research funding by newly recruited Assistant Professors: Can it be modeled as a series of uncertain events? *Acad. Med.* 79: 633-643, 2004
212. Joiner K.A., A strategy for allocating central funds to support new faculty recruitment, *Acad. Med.* 80: 218-24, 2005.
213. Joiner, K.A. Strategies for defining financial benchmarks for the research mission in academic health centers. *Acad. Med.* 80:211-217, 2005.
214. Nishikawa, Y., Quittnat, F., Stedman, T.T., Voelker, D.R., Choi, J.Y., Zahn, M., Yang, M., Pypaert, M., Joiner, K.A. and Coppens, I. (2004) Host cell lipids control cholesteryl ester synthesis and storage in intracellular *Toxoplasma*. *Cell. Microbiol.* 7:849-67, 2005.

215. Quittnat, F., Nishikawa, Y., Stedman, T.T., Voelker, D.R., Choi, J-y, Zahn, M. Murphy, R.C., Martin, W., Joiner, K.A., and Coppens, I. On the biogenesis of lipid bodies in ancient eukaryotes: synthesis of triacylglycerols by a *Toxoplasma* DGAT-1-related enzyme. *Mol. Biochem. Parasitol.* 138:107-22, 2004.
216. Gupta, N., Zahn, M.M., Coppens, I. Joiner, K.A., and Voelker, D.R. Selective disruption of phosphatidylcholine metabolism of the intracellular parasite *Toxoplasma gondii* arrests its growth. *J. Biol. Chem.* 280:16345-53, 2005
217. Massimine, K.M., Doan, L.T., Atreya, C.E., Stedman, T.T., Anderson, K.S., Joiner, K.A. and Coppens, I. *Toxoplasma gondii* is capable of exogenous folate transport. A likely expansion of the BT1 family of transmembrane proteins. *Mol. Biochem. Parasitol.* 144:44-54, 2005.
218. McIntosh, M.T., Elliott, D. and Joiner, K.A. *Plasmodium falciparum*: discovery of peroxidase positive organelles. *Exp. Parasitol.* 111: 133-6, 2005.
219. Joiner, K.A. The not-for-profit form and translational research: Kerr revisited? *J. Translational Med.* 3:19, 2005.
220. Joiner, K.A. Avoiding the winner's curse in faculty recruitments to academic health centers. *Am. J. Med.* 118:1290-4, 2005.
221. Seghal, A., Bettioli, S., Pypaert, M. Wenk, M.R., Blader, I., Kaasch, A., Joiner, K.A. and Coppens, I. Peculiarities of host cholesterol transport to the unique intracellular compartment containing *Toxoplasma gondii*. *Traffic.* 6: 1125-41, 2005.
222. Wilson, M.S., Joiner, K.A., Inzucchi, S.E., Mulligan, M., Gross, C.P., Coleman, D.L., Improving clinical productivity in the academic setting: A novel incentive plan based on utility theory. *Acad. Med.* 81:306-313, 2006.
223. Coppens, I., Dunn, J.D., Romano, J.D., Pypaert, M., Zhang, H., Boothroyd, J.C., and Joiner, K.A., *Toxoplasma gondii* sequesters lysosomes from mammalian cells in the vacuolar space. *Cell.* 125:261-274, 2006. (Faculty of 1000 – cited as top 1% of papers in all biology for 2006; commentary in *J. Cell Biol.* and *Nature*)
224. Massimine, K.M., McIntosh, M.T., Doan, L.T., Atreya, C.E., Gromer, S., Sirawaraporn, W., Elliott, D.A., Joiner, K.A., Heiner Schirmer, R. and Anderson, K.S. Eosin B as a novel antimalarial agent for drug resistant *Plasmodium falciparum*. *Antimicrob. Agents Chemo.* 50: 3132-41, 2006.
225. McIntosh, M.T., Vaid, A., Hosgood, D.H., Vijay, H., Bhattacharya, A., Baevova, P., Joiner, K.A., and Sharma, P. Traffic to the malaria parasite food vacuole. A novel pathway involving a PI3P binding protein. *J Biol Chem.* 13;282(15):11499-508, 2007.
226. Nishikawa, Y., Kawase, O., Vielemeyer, O., Suzuki, H., Joiner, K.A., Xuan, X. and Nagasawa, H. *Toxoplasma gondii* infection induces apoptosis in noninfected

- macrophages: role of nitric oxide and other soluble factors. *Parasite Immunol.* 29(7):375-85, 2007.
227. Shea, M., Jäkke, U., Liu, Q., Berry, C., Joiner, K.A., and Soldati, D. Characterization of a family of aspartic proteases and identification of a novel compartment of the secretory pathway in *Toxoplasma gondii*. *Traffic.* 8: 1018-1034, 2007.
 228. Joiner, K.A., Hiteman, S., Wormsley, S. and St Germain, P. Timing of revenue streams from newly recruited faculty: Implications for faculty retention. *Acad. Med.* 82: 1228-1238, 2007
 229. Joiner, K.A., Malan, T.P., Schloss, E.P., Flynn, S.D., and Chadwick, J.A. Phoenix Rises, with Tucson's Help: Establishing the First Four-Year Allopathic Program in the Nation's Fifth Largest City. *Acad. Med.* 82: 1126-1138, 2007.
 230. Smythe, W.A., Joiner, K.A., and Hoppe, H.C. Actin is required for endocytic trafficking in the malaria parasite *Plasmodium falciparum*. *Cell Micro.* 10: 452-64, 2008.
 231. Libecap, A., Wormsley, S., Cress, A., Matthews, M., Souza, A., and Joiner, K.A. A comprehensive space management model for facilitating programmatic research. *Acad. Med.*, 83: 207-16, 2008
 232. Elliott, D.A., McIntosh, M.T., Hosgood, H.D., Chen, S., Zhang, G. Baevova, P. and Joiner, K.A. Four distinct pathways of hemoglobin uptake in the malaria parasite, *Plasmodium falciparum*. *Proc. Natl. Acad. Sci.* 105: 2463-8, 2008.
 233. Joiner, K.A., Libecap, A., Cress, A., Wormsley, S., St. Germain, P., Berg, R. and Malan, P. Supporting the academic mission in an era of constrained resources: Approaches at the University of Arizona College of Medicine. *Acad. Med.* 83: 837-44, 2008
 234. Gupta, A., Goyal, R.K., Joiner, K.A., and Saini, S. A. Outsourcing in the healthcare industry: Information technology, intellectual property, and allied aspects. *Information Resources Management Journal.* 2008
 235. Roberts, L., Egan, T.J., Joiner, K.A. and Hoppe, H.C. Differential effects of quinoline anti-malarials on endocytosis in *Plasmodium falciparum*. *Antimicrob. Agents. Chemother.* 52:1840-1842, 2008.
 236. Joiner, K.A., A simple approach to optimize resource allocation when expanding the faculty research base. *Acad. Med.*, 84: 13-25, 2009
 237. Joiner, KA. Commentary: Evaluating faculty productivity: an interesting approach, but questions remain. *Acad. Med.* 84:1482-84, 2009.

238. Ehrenman, K., Sehgal, A., Lige, B, Stedman, T.T., Joiner, K.A., and Coppens, I. Novel roles for ATP-binding cassette G transporters in lipid redistribution in *Toxoplasma*. *Molecular Microbiology*. 76:1232-49, 2010.
239. Joiner, KA., Castellanos, N, and Wartman, S. Resource allocation in academic health centers: Creating common metrics. *Acad. Med.* 86:1084-1092, 2011.
240. Joiner, KA and Coleman, DL. Perspective: Key indicators in academic medicine: A suggested framework for analysis. *Acad. Med.*, 87:230-235, 2012.
241. Chambers, SK and Joiner, KA. Incorporating translational research into gynecologic cancers, while balancing the focus of personalized medicine. In press, *Current Multidisciplinary Oncology: Gynecologic Cancer*, ed. Kunle Odunsi and Tanja Pejovic.
241. Lige, B, Romano, JD, Sampels, V, Sonda, S., Joiner, KA, and Coppens, I, Introduction of caveolae structural proteins into the protozoan *Toxoplasma* results in the formation of heterologous caveolae but not caveolar endocytosis. *PloS One*, 7(12): e51773, 2012.
242. Sarpatwari, A. , Robertson, CT, Yokum, DV and Joiner, KA. Crowdsourcing public health experiments: A response to Jonathan Darrow's crowdsourcing clinical trials. *Minn Law Review*.
243. Robertson, CT, Yokum, DV, Sheth, N, and Joiner, KA. A randomized trial of the split benefit health insurance reform to reduce high-cost, low-value consumption. *Innovation and Entrepreneurship in Health*. 1: 5-11, 2014.
244. Joiner, KA, Kramer, T. R. and Cooper, R. A practical cost-based approach to determining reimbursement rate: A necessary component of effective payment reform. *Innovation and Entrepreneurship in Health*. 2: 9-17, 2015
245. Robertson, C.T. and Joiner, K.A. Scaling and splitting: New approaches to health insurance. *Regulation*. Cato Institute. 38 (2): 40-45, 2015
246. A problem not yet manifest: Gaps in insurance coverage of medical interventions after genetic testing. *J. Law and Bioscience*. 1-7, 2015
247. Joiner, KA and Lusch, R.L. Evolving to a service dominant logic for health care. *Innovations and Entrepreneurship in Health*. 3: 25-33, 2016
248. Thornton, A. and Joiner, K.A. Safely unsterile: Understanding the anatomical and immunologic niches of placental, urinary and vaginal microbiomes. *Am. J. Clin. Exp. Obstet. Gyn.* 3: 1-21, 2016.

249. Seckeler, M.D., Thomas, I.D., Andrews, Joiner, K., Klewer, S.E. A review of the economics of adult congenital heart disease. *Expert Rev Pharmacoecon Outcomes Res.* 2016;16(1):85-96.
250. Johnstone, C, Joiner, KA, Pierce, J. and Krouse, R.S. Mohs micrograph surgery Volume and payment patterns among dermatologists in the Medicare population, 2013. Submitted for publication
251. Gowrisankaran, G., Joiner, KA., and Lin, J. Does hospital electronic medical record adoption lead To upcoding or more accurate coding? In preparation
252. Gowrisankaran, G., Joiner, KA., and Leger, PT, Physician practice style and healthcare costs: Evidence from emergency departments. In preparation

Invited Lectures:

1983:

Sexually Transmitted Diseases Conference, Montreal, June 1983

1984:

Abbott Laboratories, March 1984

Symposium on Pathogenesis of Bacterial Diseases, Cologne, Germany, May 1984

Vaccine Conference, NIH, September 1984

Interscience Conference on Antimicrobial Agents and Chemotherapy,
Washington, D.C., October 1984

4th International Pathogenic Neisseria Conference, Assilomar, CA, November
1984

1985:

Infectious Disease Division, University of Colorado School of Medicine, January
1985

Pfizer, Groton, CT, March 1985

Cystic Fibrosis Symposium, NIH, March 1985

Federation of American Societies for Experimental Biology and Medicine,
Anaheim, CA, April 1985

Marine Biological Laboratory, "Biology of Parasitism" Course, Woods Hole, MA,
August 1985

University of New York School of Medicine, Buffalo, New York, October 1985

1986:

Cystic Fibrosis Symposium, NIH, March 1986

American Society for Microbiology, Washington, D.C., March 1986

Federation of the American Society for Experimental Biology, St. Louis, April
1986

UCAC Conference on Infectious Disease, Invermere, British Columbia, May 1986

Department of Immunology, University de Sao Paulo, Sao Paulo, Brazil, 1986

Department of Mycology, Escola Paulista, Sao Paulo, Brazil, 1986

Department of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro,
Brazil, July 1986

Marine Biological Laboratory, "Biology of Parasitism" Course, Woods Hole,
MA, August 1986

International Symposium on Parasitology and Tropical Diseases, Hamburg,
Germany, September 1986

5th International Pathogenic Neisseria Conference, Amsterdam, September 1986

Department of Immunology and Microbiology, Rush-Presbyterian Hospital,
Chicago, IL, October 1986

Doenca de Chagas, Caxambu, Brazil, November 1986

Division of Allergy, Tufts University School of Medicine, December 1986

1987:

UCLA Symposium on Bacteria-Host Cell Interaction, Park City, Utah, February 1987

American Society for Microbiology, Atlanta, Georgia, March 1987

Department of Microbiology, USUHS, Bethesda, MD, March 1987

Bacteria, Complement and the Phagocytic Cell, Acquafreda di Maratea, Italy, April 1987

University of Toronto, Toronto, Ontario, Department of Microbiology, May 1987

Channing Laboratory, Harvard University, Boston, MA, June 1987

Parasitology Gordon Conference, Plymouth, New Hampshire, August 1987

Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, October, 1987

Wayne State University, Division of Microbiology and Immunology, Detroit MI, December 1987

1988:

University of Tennessee, Microbiology and Immunology Dept., January, 1988

Molecular Aspects of Parasite Recognition, Penetration, and Survival, Worcestershire, England, February, 1988

New York University, Dept of Pathology, March 1988

Duke University, Dept of Immunology, April 1988

University of Toronto, Visiting Professor, Dept. of Medicine, April, 1988

Tufts University, Division of Experimental Medicine, May, 1988

FASEB Summer Conference, Copper Mountain, Colorado, July 1988

Yale University, Dept. of Medicine, November, 1988

1989:

Meeting on Glycophosphatidylinositol Anchored Proteins, Ubatuba, Brazil, February, 1989

University of Colorado, Graduate Student Symposium, March, 1989

UCLA Conference on "Parasites: Molecular Biology, Drug and Vaccine Design". Keystone, Colorado, April, 1989

Symposium of Recent Advances in Parasitology, Meharry Medical College, May, 1989

The Rockefeller University, New York, NY, Laboratory of Bacteriology, October, 1989

American Society for Tropical Medicine and Hygiene, Honolulu, December, 1989

1990:

State University of New York, Pathology Seminar Series, Stonybrook. April, 1990

Emory University, Infectious Disease Seminar Series, Atlanta, GA. May, 1990

Centers for Disease Control, Grand Rounds, Atlanta, GA, May, 1990

Boston University, Finland Laboratory, Infectious Disease Seminar Series Boston, MA, May, 1990

Connecticut State ID Society, Keynote Speaker, Hartford, CT. May, 1990

Marine Biological Laboratory, Biology of Parasitism Course, July, 1990

International Erlangen Workshop on Molecular Aspects of Host-Parasite Interactions. Erlangen, Germany. Sept. 1990

University of Georgia, Molecular Parasitology Symposium, November 1990
Merck Sharpe and Dohme, Rahway, N.J. November 1990
Grand Rounds, Lawrence Memorial Hospital, December 1990

1991:

Harvard Medical School, Combined Infectious Disease Rounds, January, 1991
Dartmouth College, Neurology Division, February, 1991
Centers for Disease Control, Pathogenesis Symposium, February, 1991
Washington University, Department of Medicine, Carl G. Harford Visiting
Professor, March, 1991
Washington University, Microbial Pathogenesis Lecture, Dept. of Microbiology,
March, 1991
Montana State University, Bozeman, MT. , Frank N. Nelson Lecture, March, 1991
Pathology Department, New York University, June, 1991
National Institutes of Health, Bethesda, MD. Critical Care Medicine Section, June
1991
Laboratory Medicine - Research Conference
ID Symposium
Gordon Conference on Medicinal Chemistry, August 1991
SUNY, Stonybrook, Molecular Pathogenesis Symposium, October 1991
Johns Hopkins, Molecular Parasitology Symposium, December 1991

1992:

Bristol Myers, Wallingford, CT January 1992
German Society Cell Biology, Konstanz, Germany, March 1992
Institute Pasteur, Lille, France, March 1992
Grand Rounds, Tufts University, April 1992
Montefiore Medical Center, April 1992
Sydney, Australia, University of Technology, Microbiology Dept, May 1992
Annual Meeting Royal Australasian College of Physicians, Adelaide, Australia,
May 1992
Walter and Eliza Hall Institute, Melbourne, Australia, May 1992
NATO Meeting, Toxoplasmosis, Angers, France, July 1992
Microbial Pathogenesis Gordon Conference, July 1992
5th International Congress of Cell Biology, Madrid, Spain, July 1992
Mt. Sinai Hospital, Hartford, CT. Grand Rounds Sept. 1992
CT. Pharmacy Association Annual Meeting, Symposium on Septic Shock, Dec.
1992

1993:

Hahnemann University, Microbiology and Immunology, February 1993
Bay Area Parasitology Meeting, Stanford, CA, February, 1993
Microbiology and Immunology Dept., Stanford University, February, 1993
1st Bristol Myers Symposium on Pathogenesis of Infectious Diseases, Monterey,
CA, February, 1993
FDA, April 1993
Grand Rounds, St. Vincents Hospital, May, 1993
Phagocytosis Gordon Conference, June, 1993

NY Academy of Sciences Conference on Pathogenesis, Orlanda, FL. September, 1993

1994:

Keystone Meeting on Pathogenesis of Infectious Diseases, Sante Fe, NM., January, 1994
Abington Memorial Hospital, Visiting Professor, Grand Rounds and Basic Science Lecture, Feb. 1994
University of Maryland, Visiting Professor, Grand Rounds and Basic Science Lecture, February 1994
Harvard University, Microbiology Dept., March, 1994
Tufts University, Microbiology Dept., March, 1994
George Washington University, Grand Rounds, March, 1994
Bowman Gray School of Medicine, Microbiology Dept. March, 1994
European Society for Clinical Investigation, Keynote Address, Toledo, Spain, April, 1994
University of Erlangen, Erlangen, Germany, Biochemistry Institute, April, 1994
FASEB Meeting on Pathogenesis of Infectious Diseases, Saxon River, VT, June 1994
Biology of Parasitism, Course Director, Cell Biology Section, July, 1994
Coccidiosis Meeting, Fort Collins, CO August 1994
Maine Medical Center, Portland, Maine, October 1994
Bayer Symposium, Garmisch, Germany, November 1994
Wadsworth Seminar Series, State University of New York, Albany, NY, December 1994.
Pathogenesis Symposium, American Society for Cell Biology, San Francisco, CA, December 1994

1995:

Life Sciences Lecture Series, Northwestern University, January 1995
Biological Regulatory Gordon Conference, June 1995
International Congress of Immunology, San Francisco, CA, July 1995
Biology of Parasitism, Woods Hole, MA, July 1995
Philippe Laudet INSERM Conference, France, October 1995
New York Academy Sciences, New York, NY, October 1995
Plenary Lecture, American Society Tropical Medicine & Hygiene, San Antonio, TX, November 1995
American Society of Hematology, Seattle, WA, December 1995

1996:

University of Connecticut, Department of Microbiology, January 1996
German Society for Cell Biology, Hamburg, Germany, March 1996
University of California, Los Angeles, Department of Microbiology & Immunology, April 1996
Symposium on Fellowship Training in Infectious Diseases, Miami, FL. April, 1996
Allergy and Immunology Grand Rounds, Yale University, May 1996
Visiting Professor, Duke University, Division of Infection Diseases, May 1996

4th International Toxoplasma meeting, Scotland, July 1996
Biology of Parasitism course, Woods Hole, MA, July 1996
1st International EctoATPase Meeting, Mar del Plata, Argentina, August 1996
DFG Priority Program Workshop, Molecular Mechanisms of Parasitism, Bonn,
Germany, October, 1996
Klinikum der Philipps-Universität Marburg, Marburg, Germany, October, 1996
Cell Biology Seminar, Zentrum für Molekulare Biologie, Heidelberg, Germany
Department of Medical Microbiology, University of Linköping, Linköping,
Sweden, October, 1996
Department of Medical Microbiology and Immunology, University of Göteborg,
Lundberg Lecture, Göteborg, Sweden, October 1996
Symposium on Fellowship Training, Miami, FL, November, 1996
American Society for Tropical Medicine and Hygiene, Burroughs Wellcome Fund
Symposium, Baltimore, M.D., December, 1996

1997:

Molecular and Cell Biology of Apicomplexan Parasites, Park City, Utah, January
1997
Columbia University, Department of Microbiology, March, 1997
University of Kentucky, Department of Microbiology, April, 1997
University of Chicago, Department of Pathology, April, 1997
Infectious Disease Division, University of Colorado, May, 1997.
University of Colorado, Department of Microbiology, May 1997
Albert Einstein College of Medicine, Department of Pathology, June, 1997
Bowman-Gray Symposium, Whistler Mountain Resort, British Columbia, August,
1997
Keynote Speaker, American Society for Rickettsiology. Champion, PA.
September, 1997
Infectious Diseases Society of America, September, 1997
Boston University School of Medicine, Infectious Diseases Division, October,
1997
American Society for Tropical Medicine and Hygiene, Orlando, FL. December,
1997

1998:

EMBO Conference, Protein Targeting in the Secretory Pathway, Annaberg,
Austria, January 1998
AAAS Symposium, Baltimore, MD. February, 1998
Mount Sinai School of Medicine, Infectious Diseases Division, February 1998
Philadelphia Microbiology Symposium, April 1998
Opportunistic Infections in AIDS, Keystone Symposia, April, 1998
Infectious Diseases Society of America Fellows Conference, Phoenix, May 1998
Duke University, Division of Infectious Diseases, Durham, N.C. August, 1998
Association of Subspecialty Professors, Leesburg, VA, Sept. 1998
University of Wyoming, Sept. 1998
Second Louis Pasteur Conference, Paris, October, 1998

Institute Pasteur, Lille, France, October, 1998
IDSA, Job Symposium, November, 1998, Denver, CO
IDSA, Fellows day Symposium, November, Denver, CO, 1998

1999:

ZMBH, Molecular Parasitology Symposium, Heidelberg, Germany, March, 1999
University of Virginia, Infectious Diseases and Microbiology, March 1999
American College of Chest Physicians, Orlando, FL, March, 1999
American College of Chest Physicians, Chicago, IL, March, 1999
Experimental Biology, Washington, DC, March 1999
Infectious Diseases Society of America, Meet the Professor, Orlando, FL, April,
1999
Infectious Diseases Society of America Fellows Conference, Orlando, FL, April,
1999
Clinical Immunology Section, Yale University, April, 1999
U. Texas, Southwestern, Infectious Disease Division, April, 1999
Fifth International Toxoplasma Conference, Marshall, CA, May, 1999
University of Vienna, Department of Medicine, May, 1999
St. Raphaels Hospital, New Haven, CT May 1999
Parasitology Gordon Conference, Salva Regina College, RI, June, 1999
Caxambu, Brasil, Annual Molecular Parasitology Meeting, November, 1999
Infectious Disease Society of America, Philadelphia, PA, Nov. 1999

2000:

Molecular Approaches to Malaria, Lorne, Victoria, Australia, February, 2000
New York University, Pathology Department, March 2000
Interurban Clinical Club, New Haven, CT, April, 2000
Harvard School of Public Health, Boston, MA, April 2000
Trudeau Institute, Saranac Lake, NY, September, 2000
Woods Hole Molecular Parasitology Conference, Woods Hole, MA, September
2000
Phillips Universitat, Marburg, Germany, October, 2000

2001:

Ritterson Lecture, University of Rochester, Rochester, NY, April, 2001
Infectious Diseases Society of America Fellows Conference, Hilton Head, S.C.,
April 2001
Sixth International Toxoplasma Conference, Friesing, Germany, May 2001
Rocky Mountain Laboratories, Hamilton, MT, July 2001
Malaria Gordon Conference, Oxford, England, August, 2001
University of CT, Pathogenesis Symposium, Farmington, CT, November, 2001
Memorial Sloan Kettering/Rockefeller combined conference, NY, NY, Nov. 2001
Albert Einstein School of Medicine, Nov. 2001

2002:

Department of Medicine, Business Models for Medical Research, invited, Feb.
2002
Medical Grand Rounds, Yale University School of Medicine, Feb. 2002

University of Pennsylvania combined Microbiology Conference, March, 2002
K30 Program Directors Meeting, Baltimore, M.D., April, 2002
Fifth Annual Genomics Symposium, Yale University School of Medicine, New Haven, CT. June, 2002
Ellison Foundation Symposium on Global Initiatives in Infectious Diseases, Woods Hole, MA. June, 2002
Hormonal and Neuropeptide Biosynthesis Gordon Conference, New London, N.H. July, 2002

2003:

Bruce Greene Distinguished Lecture, University of Alabama, April, 2003
Oregon Health and Sciences University, Microbiology and Immunology Dept, May, 2003
American Society for Tropical Medicine and Hygiene, Annual Meeting, Burroughs Wellcome Fund Symposium, Philadelphia, December, 2003

2004:

Frontiers in Translational Research Symposium, Tucson, August, 2004
University of Arizona Alumni Association, Tucson, September, 2004
Medical Grand Rounds, University of Arizona, Tucson, September, 2004
Nutritional Sciences Department, Tucson, September, 2004
Surgical Grand Rounds, University of Arizona, Tucson, October, 2004
Downtown Phoenix Leadership Council, Phoenix, October, 2004
American College of Physicians, Arizona Chapter, Phoenix, October, 2004
Leadership Conference, Eller College of Business, Tucson, October, 2004
Program in Integrative Medicine, Tucson, November, 2004
Greater Phoenix Leadership Council, Phoenix, November, 2004

2005:

University Healthcare Consortium symposium – Phoenix, February, 2005
American Diabetes Association Council Meeting – Tucson, March, 2005
Tucson Lion's Club, Tucson, April, 2005
University of Arizona Foundation – Phoenix, May, 2005
Arizona Latin American Medical Association – Phoenix, May, 2005
Maricopa County Medical Society Board of Directors – Phoenix, June, 2005
Greater Downtown Phoenix Leadership Board – Phoenix, June 2005
IRACDA Panel presentation – Tucson, June 2005
Arizona Med-Start Program – Phoenix, July, 2005
Scottsdale Health Care Board of Directors – Scottsdale, September, 2005
American College of Physicians, Arizona Chapter - Annual meeting – Tucson, October, 2005
History of College of Medicine Lecture – University of Arizona, Tucson, October, 2005
Frontiers in Nutritional Sciences National Symposium, Tucson, October, 2005
Pima County Medical Society – 100th Anniversary Meeting – Tucson, October, 2005
AAMC Annual Meeting – Washington, DC – November, 2005

2006:

Arizona Department of Public Health, Phoenix, February, 2006
Arizona Academy of Family Physicians, Phoenix, April, 2006
Visiting Professor, Fudan University, Shanghai, PRC, July, 2006
Visiting Professor, Shandong University, Jinan, PRC, July 2006
Desert Samaritan Hospital, Keynote Address, Mesa, AZ, May, 2006
Surgical Grand Rounds, University of Arizona, Tucson, September, 2006
Medical Grand Rounds, University of Arizona, Tucson, September, 2006
Trilateral Conference, Association of Academic Health Centers, Vancouver, B.C.,
October, 2006
AAMC Annual Meeting - Seattle, November, 2006

2007:

Keynote Address, American Academy of Asthma, Allergy and Immunology,
Dallas, January 2007
Arizona Parkinson's Disease Association, Tucson, January, 2007
Dr. G. Gill Richards Endowed Lecture, University of Utah School of Medicine,
Salt Lake City, March, 2007
Infectious Disease Society of America, San Diego, October, 2007

2008:

Eureka Consensus conference, Ortigia, Italy, May 2008
Symposium Chair and speaker: "Beyond Cardiovascular Disease: Statins,
Cholesterol and Infectious Diseases" International Congress of
Infectious Disease, Kuala Lumpur, June, 2008
Program Chair, Annual Meeting, Association of Academic Health Centers,
Meeting Title: "Integration in Academic Health Centers", Scottsdale,
AZ, October, 2008

2009:

Association of Independent Academic Medical Centers – "The Dean's
Perspective", March, 2009, Tucson, AZ
Technology Cores: Designs for Efficient Management and Utilization, NIH public
workshop, Bethesda, MD, July, 2009

2010:

What can we learn from health care systems in other countries?
Tucson, Arizona Healthcare Academy February, 2010
The role of the academic medical center in healthcare reform. Tucson, March
2010
Pay for performance in healthcare. Tucson, May 2010
Regulation in healthcare - More is good for you. Scottsdale, AZ November, 2010

2011:

Service dominant logic: Bridging health and health care. Singapore, August, 2011
Health Care Reform - Arizona Society of Woman Accountants - November, 2011

2012:

Advances in Quality in Medicine - Arizona Health Forum, Tucson, AZ - March, 2012

UBRP Politics of Health, Science and Education Panel, Tucson, AZ, October, 2012

RealShare Panel, Scottsdale, AZ, November, 2012

2013:

Evolving Concepts of Health Care Delivery and Their Relationship to Resource Needs. Scottsdale, AZ, Scottsdale, AZ, February 2013

Keynote address, Alpha Epsilon Delta Initiation, Tucson, AZ, 2013

Evolving Concepts of Health Care Delivery and Their Relationship to Resource Need, San Diego, CA. May 2013

Evolving Concepts of Health Care Delivery and Their Relationship to Resource Needs. Phoenix, AZ, June 2013

Evolving Concepts of Health Care Delivery and Their Relationship to Resource Needs, October, 2013. Los Angeles, CA

Connecting Health, Health Care, and Public Health Through Service Dominant Logic. December, 2013. Kochy, Kerala, India.

2014:

The Affordable Care Act, Tucson Rotary Club, Tucson, AZ January, 2014

Debate: Is Obamacare the disease or the cure? University of Arizona Objectivists Club. Tucson, AZ, February, 2014

Health Care Reform in the US, Shanghai, China, Nov 2015

The Human Microbiome. Shanghai, China, Nov 2015

2015:

Global Health Program Symposium. Feb, 2015

CASHE, Phoenix, June 2015